CUMULATIVE SUPPLEMENT 8

JAN'94-AUG'94

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DRUG INFORMATION RESOURCES

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- USP Monograph Title Additions or Changes
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

Cumulative Supplement 8

AUGUST 1994

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

CUMULATIVE SUPPLEMENT 8

AUGUST 1994

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 14th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing overstruck print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∂ " symbol to designate their non-marketed status. All products having a " ∂ " symbol in the 12th Cumulative Supplement of the 14th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 15th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ADRIA LABORATORIES DIV ERBAMONT INC (ADRIA)	PHARMACIA INC (PHARMACIA)
BANNER GELATIN PRODUCTS CORP (BANNER GELATIN)	BANNER PHARMACAPS INC (BANNER PHARMACAPS)
CLONMEL CHEMICALS CO LTD (CLONMEL)	CLONMEL HEALTHCARE LIMITED (CLONMEL)
DUPONT PHARMACEUTICALS (DUPONT)	DUPONT MERCK PHARMACEUTICALS CO (DUPONT MERCK)
GYNEX INC (GYNEX)	BTG PHARMACEUTICALS CORP SUB BIOTECHNOLOGY GENERAL CORP (BTG PHARMS)
KABI PHARMACIA INC (KABI)	PHARMACIA INC (PHARMACIA)
MALLINCKRODT SPECIALTY CHEMICALS CO (MALLINCKRODT)	MALLINCKRODT CHEMICAL INC (MALLINCKRODT)
NORTH AMERICAN CHEMICAL CORP (NORTH AM CHEM)	GOLDEN PHARMACEUTICALS INC (GOLDEN PHARM)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
PHARMACEUTICAL BASICS INC (PHARM BASICS)	ROSEMONT PHARMACEUTICAL CORPORATION (ROSEMONT PHARM)
RICHLYN LABORATORIES INC (RICHLYN)	GLOBAL PHARMACEUTICAL CORPORATION (GLOBAL PHARM)
SQUIBB DIAGNOSTICS (SQUIBB)	BRACCO DIAGNOSTICS INC (BRACCO)

1.4 NEW INDICATIONS FOR PREVIOUSLY APPROVED DRUG PRODUCTS

When an application is submitted to FDA for a new indication for a drug product that duplicates a drug product (same active moiety, same salt, same formulation, or same combination) already approved or marketed in the United States by the same firm, the application is either submitted as a supplement to the original NDA (if the clinical expertise for the review of the new indication resides in the same division that reviewed the original NDA), or as a "Type 6 NDA" and assigned a new NDA number (if the clinical expertise for the review of the new indication resides in another review division). When an application is submitted to FDA for a new indication for a drug product that duplicates a drug product (same active moiety, same salt, same formulation, or same combination) already approved or marketed in the United States by a different firm, the application is classified as "Type 6" and assigned a new NDA number.For administrative purposes, FDA has been listing all "Type 6 NDA's" in the *Approved Drug Products with Therapeutic Equivalence Evaluations*, (ADP), even when the application was submitted by the original NDA holder. However, FDA has determined that the practice of listing a separate "Type 6 NDA" number in the ADP when the applicant is the original NDA holder may cause confusion to the ADP reader.

Accordingly, to prevent confusion and to eliminate duplicity of data, the approval of an application for a new indication for a previously approved drug product submitted by the original NDA holder will no longer be listed in the ADP. Any exclusivity awarded for that approval will be shown in the Patent and Exclusivity Information Addendum under the original NDA number. However, approval of an application for a new indication submitted by an applicant other than the original NDA holder will be shown in the appropriate drug product list of the ADP. Any exclusivity awarded will be shown under the NDA number of the new applicant.

All approvals of "Type 6" applications submitted by the original NDA holder currently in the ADP are listed in the table below. For reference purposes, the original NDA number is listed next to the corresponding "Type 6 NDA Number". This data ("Type 6 NDA Number") will continue to be listed in the remaining Cumulative Supplements to the 14th Edition of the ADP; but it will not appear in the 15th Edition of the ADP.

TYPE 6 NDA NUMBER	ORIGINAL NDA NUMBER	ACTIVE INGREDIENT (TRADE NAME)	DOSAGE FORM (ROUTE)
17-117	16-020	AMANTADINE HCL (SYMMETREL)	CAPSULE (ORAL)
17-118	16-023	AMANTADINE HCL (SYMMETREL)	SYRUP (ORAL)
50-697	50-662	CLARITHROMYCIN (BIAXIN)	TABLET (ORAL)
19-576	19-084	KETOCONAZOLE (NIZORAL)	CREAM (TOPICAL)
19-648	19-084	KETOCONAZOLE (NIZORAL)	CREAM (TOPICAL)
18-064	18-063	NADOLOL (CORGARD)	TABLET (ORAL)
20-109	19-886	NAFARELIN ACETATE (SYNAREL)	SPRAY, METERED (NASAL)
20-223	19-057	TERAZOSIN HCL (HYTRIN)	TABLET (ORAL)

1.5 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF AUGUST 1994.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1993) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1993	MAR 1994	JUN 1994	SEP 1994
DRUG PRODUCTS LISTED	9140	9153	9079	
SINGLE SOURCE	2144 (23.5%)	2151 (23.5%)	2150 (23.7%)	
MULTISOURCE	6996 (76.5%)	7002 (76.5%)	6929 (76.3%)	
THERAPEUTICALLY EQUIVALENT	6292 (68.8%)	6306 (68.9%)	6290 (69.3%)	
NOT THERAPEUTICALLY EQUIVALENT	527 (5.8%)	513 (5.6%)	458 (5.0%)	
EXCEPTIONS[1]	177 (1.9%)	183 (2.0%)	181 (2.0%)	
NEW MOLECULAR ENTITIES APPROVED	--	6	5	
NUMBER OF APPLICANTS	526	528	490	

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
/MEDIGESIC PLUS/

/AB/	/US/CHEM/	/325MG;50MG;40MG/	/N89115/001/ /JAN/14,/1986/
	@ US CHEM	325MG;50MG;40MG	N89115 001 JAN 14, 1986

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

AT	BAUSCH AND LOMB	2%;0.79%	N40063 001 FEB 25, 1994

/BOROFAIR/

/AT/	/PHARMAFAIR/	/2%;0.79%/	/N88606/001/ /AUG/21,/1985/
	@ PHARMAFAIR	2%;0.79%	N88606 001 AUG 21, 1985

DOMEBORO

>DLT>	/AT/	/MILES/	/2%;0.79%/	/N84476/001/
>ADD>	AT +	MILES	2%;0.79%	N84476 001

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL
ACETYLCYSTEINE

>ADD>	AN	ABBOTT	10%	N73664 001 AUG 30, 1994
>ADD>				
>ADD>	AN		20%	N74037 001 AUG 30, 1994
>ADD>				

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL
SEMPREX-D

+	BURROUGHS WELLCOME	8MG;60MG	N19806 001 MAR 25, 1994

ALBUTEROL SULFATE

TABLET; ORAL
ALBUTEROL SULFATE

/AB/	/WARNER/CHILCOTT/	/EQ 2MG BASE/	/N72817/001/ /JAN/09,/1990/
/AB/		/EQ 4MG BASE/	/N72818/001/ /JAN/09,/1990/
	@ WARNER CHILCOTT	EQ 2MG BASE	N72817 001 JAN 09, 1990
	@	EQ 4MG BASE	N72818 001 JAN 09, 1990

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	MYLAN	0.25MG	N74215 001 JAN 27, 1994
AB		0.5MG	N74215 002 JAN 27, 1994
AB		1MG	N74215 003 JAN 27, 1994
AB		2MG	N74215 004 JAN 27, 1994
AB	NOVOPHARM	0.25MG	N74085 001 FEB 16, 1994
AB		0.5MG	N74085 002 FEB 16, 1994
AB		1MG	N74085 003 FEB 16, 1994
AB	ZENITH LABS	0.25MG	N74294 001 JUL 29, 1994
AB		0.5MG	N74294 002 JUL 29, 1994
AB		1MG	N74294 003 JUL 29, 1994
AB		2MG	N74294 004 JUL 29, 1994

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN

AP	BEDFORD	EQ 50MG BASE/ML	N63313 001 APR 11, 1994
AP		EQ 250MG BASE/ML	N63315 001 APR 11, 1994

'DUE TO PROGRAMMING CHANGES, EACH FIELD ON A PREVIOUSLY DELETED OR CURRENTLY DELETED DRUG PRODUCT LINE HAS BEEN CHANGED TO ONLY SHOW THE OVERSTRUCK SYMBOL BEFORE AND AFTER EACH FIELD RATHER THAN OVER EACH CHARACTER OF THE ENTIRE ENTRY.

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN

/AP/	/ELKINS/SINN/	/EQ 50MG BASE/ML/	/N63274/001/ /MAY/18,/1992/
AP +	ELKINS SINN	EQ 50MG BASE/ML	N63274 001 MAY 18, 1992
/AP/		/EQ 250MG BASE/ML/	/N63275/001/ /MAY/18,/1992/
AP +		EQ 250MG BASE/ML	N63275 001 MAY 18, 1992

/AMIKIN/

/AP//+//BRISTOL/		/EQ 50MG BASE/ML/	/N50495/001/
/AP/		/EQ 50MG BASE/ML/	/N62562/001/ /SEP/20,/1984/
/AP//+/		/EQ 250MG BASE/ML/	/N50495/002/
/AP/		/EQ 250MG BASE/ML/	/N62562/002/ /SEP/20,/1984/
@	APOTHECON	EQ 50MG BASE/ML	N50495 001
@		EQ 250MG BASE/ML	N50495 002
@	BRISTOL	EQ 50MG BASE/ML	N62562 001 SEP 20, 1984
@		EQ 250MG BASE/ML	N62562 002 SEP 20, 1984

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

/ABBOTT/		/5%;25GM/100ML/	/N19565/001/ /DEC/17,/1986/
@	ABBOTT	5%;25GM/100ML	N19565 001 DEC 17, 1986

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE

/AP/	/FUJISAWA/	/25MG/ML/	/N87886/001/ /AUG/30,/1983/
@	FUJISAWA	25MG/ML	N87886 001 AUG 30, 1983
AP	KING PHARMS	25MG/ML	N86606 001
/AP/	/SMITHKLINE/BEECHAM/	/25MG/ML/	/N86606/001/

AMINOPHYLLINE

TABLET; ORAL
AMINOPHYLLINE

/BD/	/LANNETT/	/100MG/	/N84588/001/
/BD/		/200MG/	/N84588/002/
@	LANNETT	100MG	N84588 001
@		200MG	N84588 002
AB	RICHLYN	100MG	N84574 001
AB		200MG	N84576 001
/BD/		/100MG/	/N84574/001/
/BD/		/200MG/	/N84576/001/

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL
PASER

+	JACOBUS	4GM/PACKET	N74346 001 JUN 30, 1994

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

/AB/	/LEMMON/	/10MG/	/N86610/001/
/AB/		/25MG/	/N86859/001/
/AB/		/50MG/	/N86857/001/
/AB/		/75MG/	/N86860/001/
/AB/		/100MG/	/N86854/001/
/AB/		/150MG/	/N86853/001/
@	LEMMON	10MG	N86610 001
@		25MG	N86859 001
@		50MG	N86857 001
@		75MG	N86860 001
@		100MG	N86854 001
@		150MG	N86853 001

AMOXICILLIN

CAPSULE; ORAL
POLYMOX

AB	APOTHECON	250MG	N63099 001 MAR 20, 1992
AB		500MG	N63099 002 MAR 20, 1992
/AB/	/BRISTOL/MYERS/	/250MG/	/N63099/001/ /MAR/20,/1992/
/AB/		/500MG/	/N63099/002/ /MAR/20,/1992/

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL
/POLYMOX/

/AB/	/BRISTOL/	/125MG/5ML/	/N61851/001/
/AB/		/125MG/5ML/	/N62323/001/
/AB/		/250MG/5ML/	/N61851/002/
/AB/		/250MG/5ML/	/N62323/002/
	@ APOTHECON	125MG/5ML	N61851 001
	@	125MG/5ML	N62323 001
	@	250MG/5ML	N61851 002
	@	250MG/5ML	N62323 002

AMPHETAMINE SULFATE

/TABLET;/ORAL/
/AMPHETAMINE/SULFATE/

	/LANNETT/	/5MG/	/N83901/001/ /AUG/31,/1984/
		/10MG/	/N83901/002/ /AUG/31,/1984/
	@ LANNETT	5MG	N83901 001 AUG 31, 1984
	@	10MG	N83901 002 AUG 31, 1984

AMPHOTERICIN B

INJECTABLE; INJECTION
AMPHOTERICIN B

/AP/	/FUJISAWA/	/50MG/VIAL/	/N62728/001/ /APR/13,/1987/
	@ FUJISAWA	50MG/VIAL	N62728 001 APR 13, 1987

AMPICILLIN/AMPICILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL
POLYCILLIN

	@ APOTHECON	EQ 125MG BASE/5ML	N62297 001
	@	EQ 250MG BASE/5ML	N62297 002
/AB/	/BRISTOL/	/EQ 125MG BASE/5ML/	/N62297/001/
/AB/		/EQ 250MG BASE/5ML/	/N62297/002/

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
/M.V.C. 9+3/

/AP/	/FUJISAWA/	/10MG/ML;0.006MG/ML;0.5UGM/ML;/ /1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/ /0.4MG/ML;0.36MG/ML;0.3MG/ML;/ /330 UNITS/ML;1 IU/ML/	/N18440/002/ /AUG/08,/1985/
	@ FUJISAWA	10MG/ML;0.006MG/ML;0.5UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	N18440 002 AUG 08, 1985

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	GENPHARM	50MG	N74126 001 MAR 23, 1994
AB		100MG	N74126 002 MAR 23, 1994
AB	INVAMED	25MG	N74265 001 FEB 28, 1994
AB		50MG	N74265 002 FEB 28, 1994
AB		100MG	N74265 003 FEB 28, 1994

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
/LOFENE/

/AA/	/LANNETT/	/0.025MG;2.5MG/	/N85372/001/
	@ LANNETT	0.025MG;2.5MG	N85372 001

BACITRACIN

OINTMENT; OPHTHALMIC
BACITRACIN

/AT/	/PHARMADERM/	/500 UNITS/GM/	/N62158/001/
	@ PHARMADERM	500 UNITS/GM	N62158 001
/AT/	/PHARMAFAIR/	/500 UNITS/GM/	/N62453/001/ /MAR/28,/1984/
	@ PHARMAFAIR	500 UNITS/GM	N62453 001 MAR 28, 1984

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	ROYCE	**10MG**	**N73092 001** JAN 28, 1994
AB		**20MG**	**N73093 001** JAN 28, 1994

BENZYL BENZOATE

/EMULSION;/TOPICAL/
/BENZYL/BENZOATE/

/+//LANNETT/	/50%/	/N84535/001/
@ LANNETT	50%	N84535 001

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL
/DIPROLENE/

/+//SCHERING/	/EQ/0.05%/BASE/	/N19408/001/ /JAN/31,/1986/
@ SCHERING	EQ 0.05% BASE	N19408 001 JAN 31, 1986

GEL; TOPICAL
DIPROLENE

+ SCHERING	EQ 0.05% BASE	N19408 002 NOV 22, 1991

BETAMETHASONE VALERATE

OINTMENT; TOPICAL
BETAMETHASONE VALERATE

/B*/	/CLAY/PARK/	/EQ/0.1%/BASE/	/N71478/001/ /DEC/23,/1987/
	@ CLAY PARK	EQ 0.1% BASE	N71478 001 DEC 23, 1987

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

/**AA**/	/LANNETT/	/**5MG**/	/N84702/001/
/**AA**/		/**10MG**/	/N84712/001/
/**AA**/		/**25MG**/	/N84074/001/
	@ LANNETT	5MG	N84702 001
	@	10MG	N84712 001
	@	25MG	N84074 001

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
DIMETANE-DX

/**AA**/	/ROBINS/AH/	/**2MG/5ML**;**10MG/5ML**;/ /**30MG/5ML**/	/N11694/007/ /MAR/29,/1984/

BUDESONIDE

AEROSOL, METERED; NASAL
RHINOCORT

+	ASTRA	0.05MG/INH	N20233 001 FEB 14, 1994

BUTABARBITAL SODIUM

ELIXIR; ORAL
/BUTALAN/

/LANNETT/	/33.3MG/5ML/	/N85880/001/
@ LANNETT	33.3MG/5ML	N85880 001

TABLET; ORAL
BUTISOL SODIUM

/**AA**/	/WALLACE/	/**100MG**/	/N00793/005/
	WALLACE	100MG	N00793 005
	SODIUM BUTABARBITAL		
/**AA**/	/LANNETT/	/**100MG**/	/N85881/001/
	@ LANNETT	100MG	N85881 001
/**AA**/	/ZENITH/	/**30MG**/	/N84040/001/
	@ ZENITH	30MG	N84040 001

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

	MIGERGOT		
BR	G AND W LABS	100MG;2MG	N86557 001 OCT 04, 1983
	/WIGRAINE/		
/BR/	/ORGANON/	/100MG;2MG/	/N86557/001/ /OCT/04,/1983/

CALCIFEDIOL

CAPSULE; ORAL

	CALDEROL		
+	ORGANON	0.05MG	N18312 002
		0.02MG	N18312 001

CALCIFEDIOL, ANHYDROUS

	/CAPSULE;/ORAL/		
	/CALDEROL/		
	/+//ORGANON/	/0.05MG/	/N18312/002/
		/0.02MG/	/N18312/001/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20171 001 AUG 19, 1992

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20171 002 AUG 19, 1992

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20171 003 AUG 19, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER	18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20183 001 DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	BAXTER	18.3MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20183 002 DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	BAXTER	18.3MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20183 003 DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	BAXTER	18.3MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20183 004 DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER	18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N17512 004

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	ABBOTT	18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 001 JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	ABBOTT	18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 002 JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	ABBOTT	18.4MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 003 JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	ABBOTT	18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 004 JUN 13, 1994

CARBACHOL

/INJECTABLE;/INJECTION/
/CARBACHOL/
/@/PHARMAFAIR/ /0.01%/ /N70292/001/ >ADD>
/MAY/21,/1986/ >ADD>

/MIOSTAT/
/+//ALCON/ /0.01%/ /N16968/001/

SOLUTION; INTRAOCULAR
CARBACHOL
@ PHARMAFAIR 0.01% N70292 001
MAY 21, 1986

MIOSTAT
+ ALCON 0.01% N16968 001

CARBAMAZEPINE

SUSPENSION; ORAL
TEGRETOL
+ BASEL PHARMS 100MG/5ML N18927 001
DEC 18, 1987

/+//GEIGY/ /100MG/5ML/ /N18927/001/
/DEC/18,/1987/

TABLET; ORAL
TEGRETOL
AB + BASEL PHARMS **200MG** **N16608 001**
/AB///+//GEIGY/ **/200MG/** /N16608/001/

TABLET, CHEWABLE; ORAL
TEGRETOL
AB + BASEL PHARMS **100MG** **N18281 001**
/AB///+//GEIGY/ **/100MG/** /N18281/001/

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA
AB SCS **10MG;100MG** **N74080 001**
MAR 25, 1994

AB **25MG;100MG** **N74080 002**
MAR 25, 1994

AB **25MG;250MG** **N74080 003**
MAR 25, 1994

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR
MERCK SHARP DOHME 25MG;100MG N19856 002
DEC 24, 1992

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL
/@/ZENITH/ /EQ/500MG/BASE/ /N62766/001/
/MAR/03,/1987/
AB APOTHECON **EQ 500MG BASE** **N62291 001**
AB ZENITH **EQ 500MG BASE** **N62766 001**
MAR 03, 1987

/ULTRACEF/
/AB/ /BRISTOL/ **/EQ 500MG BASE/** /N62291/001/

POWDER FOR RECONSTITUTION; ORAL
CEFADROXIL
AB APOTHECON **EQ 125MG BASE/5ML** **N62334 001**
AB **EQ 250MG BASE/5ML** **N62334 002**
AB **EQ 500MG BASE/5ML** **N62334 003**
/ULTRACEF/
/AB/ /BRISTOL/ **/EQ 125MG BASE/5ML/** /N62334/001/
/AB/ **/EQ 250MG BASE/5ML/** /N62334/002/
/AB/ **/EQ 500MG BASE/5ML/** /N62334/003/

TABLET; ORAL
CEFADROXIL
/@/ZENITH/ /EQ/1GM/BASE/ /N62774/001/
/APR/08,/1987/
AB ZENITH **EQ 1GM BASE** **N62774 001**
APR 08, 1987

ULTRACEF
AB APOTHECON **EQ 1GM BASE** **N62390 001**
JUN 10, 1982

/AB/ /BRISTOL/ **/EQ 1GM BASE/** /N62390/001/
/JUN/10,/1982/

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

/AP/	/FUJISAWA/	/EQ 500MG BASE/VIAL/	/N62688/002/ /NOV/17,/1986/	
/AP/		/EQ 1GM BASE/VIAL/	/N62688/003/ /NOV/17,/1986/	
/AP/		/EQ 10GM BASE/VIAL/	/N62688/004/ /NOV/17,/1986/	
/AP/		/EQ 20GM BASE/VIAL/	/N62688/005/ /AUG/03,/1987/	
	@ FUJISAWA	EQ 500MG BASE/VIAL	N62688 002 NOV 17, 1986	
	@	EQ 1GM BASE/VIAL	N62688 003 NOV 17, 1986	
	@	EQ 10GM BASE/VIAL	N62688 004 NOV 17, 1986	
	@	EQ 20GM BASE/VIAL	N62688 005 AUG 03, 1987	

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

	FUJISAWA	EQ 1GM BASE/VIAL	N63294 002 MAR 31, 1994
		EQ 2GM BASE/VIAL	N63294 003 MAR 31, 1994

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL
CEFTIN

+	GLAXO	EQ 125MG BASE/5ML	N50672 001 JUN 30, 1994

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
/SEFFIN/

/AP/	/GLAXO/	/EQ 1GM BASE/VIAL/	/N62435/001/ /NOV/15,/1983/	>ADD> >DLT>	
/AP/		/EQ 2GM BASE/VIAL/	/N62435/002/ /NOV/15,/1983/		
/+/		/EQ/10GM/BASE/VIAL/	/N62435/003/ /NOV/15,/1983/		

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
/SEFFIN/

@ GLAXO	EQ 1GM BASE/VIAL	N62435 001 NOV 15, 1983
@	EQ 2GM BASE/VIAL	N62435 002 NOV 15, 1983
@	EQ 10GM BASE/VIAL	N62435 003 NOV 15, 1983

CHLORAMPHENICOL

OINTMENT; OPHTHALMIC
/CHLOROFAIR/

/AT/	/PHARMAFAIR/	/1%/		/N62439/001/ /APR/21,/1983/
	@ PHARMAFAIR	1%		N62439 001 APR 21, 1983

SOLUTION/DROPS; OPHTHALMIC
/CHLOROFAIR/

/AT/	/PHARMAFAIR/	/0.5%/		/N62437/001/ /APR/14,/1983/
	@ PHARMAFAIR	0.5%		N62437 001 APR 14, 1983

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
PERIDEX

AT	+ PROCTER AND GAMBLE	0.12%		**N19028 001** AUG 13, 1986

PERIOGARD

AT	COLGATE PALMOLIVE	0.12%		**N73695 001** JAN 14, 1994

CHLORMERODRIN, HG-197

INJECTABLE; INJECTION
CHLORMERODRIN HG 197

@ BRACCO	0.6-1.4mCi/ML	N17269 001		
/@/SQUIBB/	/0.6-1.4MCI/ML/	/N17269/001/		

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

/AA/	/ZENITH/	/4MG/	/N80779/001/
	@ ZENITH	4MG	N80779 001

CHLORTHALIDONE

TABLET; ORAL
THALITONE

+	HORUS THERAP	15MG	N19574 001 DEC 20, 1988
		/15MG/	/N19574/001/ /DEC/20,/1988/

CHOLESTYRAMINE

TABLET; ORAL
QUESTRAN

+	BRISTOL MYERS SQUIBB	EQ 1GM RESIN	N73403 001 APR 28, 1994

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	ENDO LABS	200MG	N74281 001 MAY 17, 1994
AB		300MG	N74281 002 MAY 17, 1994
AB		400MG	N74281 003 MAY 17, 1994
AB		800MG	N74329 001 MAY 17, 1994
AB	MYLAN	200MG	N74246 001 MAY 17, 1994
AB		300MG	N74246 002 MAY 17, 1994
AB		400MG	N74246 003 MAY 17, 1994
AB		800MG	N74246 004 MAY 17, 1994

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	NOVOPHARM	200MG	N74151 001 MAY 17, 1994
AB		300MG	N74151 002 MAY 17, 1994
AB		400MG	N74151 003 MAY 17, 1994
AB		800MG	N74463 001 MAY 17, 1994
	TAGAMET		
AB	SMITHKLINE BEECHAM	200MG	N17920 002
AB		300MG	N17920 003
AB		400MG	N17920 004 DEC 14, 1983
AB +		800MG	N17920 005 APR 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
>ADD< CIMETIDINE HCL

>ADD< AP	ENDO LABS	EQ 300MG BASE/2ML	N74005 001 AUG 31, 1994
>ADD<	TAGAMET		
>ADD< AP +	SMITHKLINE BEECHAM	EQ 300MG BASE/2ML	N17939 002

SOLUTION; ORAL
CIMETIDINE HCL

AA	BARRE	EQ 300MG BASE/5ML	N74176 001 JUN 01, 1994
	TAGAMET		
AA	SMITHKLINE BEECHAM	EQ 300MG BASE/5ML	N17924 001

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	LEMMON	EQ 0.5MG BASE/5ML	N73399 001 JUN 30, 1994

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	BEDFORD	EQ 150MG BASE/ML	N63163 001 JUN 30, 1994

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

/AP/	/DUPONT/	/EQ 150MG BASE/ML/	/N62908/001/	
			/FEB/01,/1989/	
	@ DUPONT MERCK	EQ 150MG BASE/ML	N62908 001	
			FEB 01, 1989	
/AP/	/FUJISAWA/	/EQ 150MG BASE/ML/	/N62747/001/	
			/JUN/03,/1988/	
	@ FUJISAWA	EQ 150MG BASE/ML	N62747 001	
			JUN 03, 1988	

>ADD> SWAB; TOPICAL
>ADD> CLEOCIN

>ADD>		UPJOHN	EQ 1% BASE	N50537 002
>ADD>				FEB 22, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB		COPLEY	0.05%	N74087 001
				FEB 16, 1994
>ADD> AB		NMC	0.05%	N74139 001
>ADD>				AUG 03, 1994

TEMOVATE

AB	+	GLAXO	0.05%	N19322 001
				DEC 27, 1985
AB	+		0.05%	N20340 001
				JUN 17, 1994

GEL; TOPICAL
TEMOVATE

	+	GLAXO	0.05%	N20337 001
				APR 29, 1994

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

AB		COPLEY	0.05%	N74089 001
				FEB 16, 1994
>ADD> AB		NMC	0.05%	N74128 001
>ADD>				AUG 03, 1994

TEMOVATE

AB	+	GLAXO	0.05%	N19323 001
				DEC 27, 1985

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
ANAFRANIL

+	BASEL PHARMS	75MG	N19906 003
			DEC 29, 1989
		25MG	N19906 001
			DEC 29, 1989
		50MG	N19906 002
			DEC 29, 1989
/+/	/CIBA/	/75MG/	/N19906/003/
			/DEC/29,/1989/
		/25MG/	/N19906/001/
			/DEC/29,/1989/
		/50MG/	/N19906/002/
			/DEC/29,/1989/

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC W/ CODEINE

AA	PENNEX	10MG/5ML;5MG/5ML;	
		6.25MG/5ML	N88896 001
			JAN 04, 1985
/@/		/10MG/5ML;5MG/5ML;/	
		/6.25MG/5ML/	/N88896/001/
			/JAN/04,/1985/

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE W/ CODEINE

AA	PENNEX	10MG/5ML;6.25MG/5ML	N88875 001
			DEC 17, 1984
/@/		/10MG/5ML;6.25MG/5ML/	/N88875/001/
			/DEC/17,/1984/

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL
COLESTID

	UPJOHN	1GM	N20222 001
			JUL 19, 1994

CORTISONE ACETATE

INJECTABLE; INJECTION
/CORTISONE/ACETATE/

/BP/ /STERIS/	/25MG/ML/	/N85677/001/	
/BP/	/50MG/ML/	/N85677/002/	
/BP/ /STERIS/	/25MG/ML/	/N83147/003/	
/BP/	/50MG/ML/	/N83147/004/	
@ STERIS	25MG/ML	N83147 003	
@	25MG/ML	N85677 001	
@	50MG/ML	N83147 004	
@	50MG/ML	N85677 002	
/BP/ /UPJOHN/	/25MG/ML/	/N08126/002/	
@ UPJOHN	25MG/ML	N08126 002	
CORTONE			
/BP/ /MSD/	/25MG/ML/	/N07110/002/	
/BP/+/	/50MG/ML/	/N07110/003/	
+ MSD	50MG/ML	N07110 003	
	25MG/ML	N07110 002	

TABLET; ORAL
CORTISONE ACETATE

>DLT >	/BP/ /INWOOD/	/25MG/	/N80731/001/	
>ADD >	@ INWOOD LABS	25MG	N80731 001	

CROMOLYN SODIUM

SOLUTION; INHALATION
CROMOLYN SODIUM

AN	DEY	**10MG/ML**	**N74209 001**	
			APR 26, 1994	

INTAL

AN	+ FISONS	**10MG/ML**	**N18596 001**	
			MAY 28, 1982	

CYANOCOBALAMIN, CO-57

CAPSULE; ORAL
RUBRATOPE-57

>ADD >	BRACCO	0.5-1uCi	N16089 002	
>DLT >	/SQUIBB/	/0.5-1/UCI/	/N16089/002/	

CYANOCOBALAMIN, CO-60

CAPSULE; ORAL
RUBRATOPE-60

>ADD >	@ BRACCO	0.5-1uCi	N16090 002	
>DLT >	/@/SQUIBB/	/0.5-1/UCI/	/N16090/002/	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CYCLOGYL

>DLT >/**AT**//+//ALCON/		**/0.5%/**	/N84109/001/	
>ADD >	+ ALCON	0.5%	N84109 001	

PENTOLAIR

AT	BAUSCH AND LOMB	**1%**	**N40075 001**	
			APR 29, 1994	
>DLT >/**AT**/	/PHARMAFAIR/	**/0.5%/**	/N88643/001/	
>DLT >			/FEB/09,/1987/	
>DLT >/**AT**/		**/1%/**	/N88150/001/	
>DLT >			/FEB/25,/1983/	
>ADD >	@ PHARMAFAIR	0.5%	N88643 001	
>ADD >			FEB 09, 1987	
>ADD >	@	1%	N88150 001	
>ADD >			FEB 25, 1983	

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL

/**AA**/	/CHELSEA/LABS/	**/4MG/**	/N86165/001/	
	@ CHELSEA LABS	4MG	N86165 001	

>ADD > CYSTEAMINE BITARTRATE

>ADD > CAPSULE; ORAL
>ADD > CYSTAGON

>ADD >	+ MYLAN	EQ 150MG BASE	N20392 002	
>ADD >			AUG 15, 1994	
>ADD >		EQ 50MG BASE	N20392 001	
>ADD >			AUG 15, 1994	

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE

+ BULL	20MG/ML	N72945 001	
		FEB 28, 1994	

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE

>_ADD_>	**AP**	CETUS BEN VENUE	**1GM/VIAL**	**N74245 001**
>_ADD_>				AUG 31, 1994
>_ADD_>	**AP**		**2GM/VIAL**	**N74245 002**
>_ADD_>				AUG 31, 1994

CYTOSAR-U

>_ADD_>	**AP**	+ UPJOHN	**1GM/VIAL**	**N16793 003**
>_ADD_>				DEC 21, 1987
>_ADD_>	**AP**	+	**2GM/VIAL**	**N16793 004**
>_ADD_>				DEC 21, 1987

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN

+ MERCK SHARP DOHME	0.5MG/VIAL	N50682 001
/+//MSD/	/0.5MG/VIAL/	/N60467/001/

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE

+ RHONE POULENC RORER	0.15MG/INH	N20355 001
		MAR 07, 1994

DESONIDE

OINTMENT; TOPICAL
DESONIDE

>_ADD_>	**AB**	TARO PHARMS	**0.05%**	**N74254 001**
>_ADD_>				AUG 03, 1994

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
DEXASPORIN

AT	BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64063 001**
			JUL 25, 1994

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL
/DECADRON/

/+//MSD/	/EQ/0.1MG/PHOSPHATE/INH/	/N14242/001/

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL
DEXACORT

+ MEDEVA	EQ 0.1MG PHOSPHATE/INH	N14242 001

AEROSOL, METERED; INHALATION
/DECADRON/

/+//MSD/	/EQ/0.1MG/PHOSPHATE/INH/	/N13413/001/

DEXACORT

+ MEDEVA	EQ 0.1MG PHOSPHATE/INH	N13413 001

DEXTROAMPHETAMINE SULFATE

/ELIXIR;/ORAL/
/DEXEDRINE/

/SMITHKLINE/BEECHAM/	/5MG/5ML/	/N83902/001/
@ SMITHKLINE BEECHAM	5MG/5ML	N83902 001

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

/**AA**/	/LANNETT/	/**5MG**/	/N83903/001/
/**AA**/		/**10MG**/	/N83903/003/
@ LANNETT		5MG	N83903 001
@		10MG	N83903 003
		/15MG/	/N85652/001/
@		15MG	N85652 001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE W/ DEXTROMETHORPHAN

AA	PENNEX	**15MG/5ML;6.25MG/5ML**	**N88864 001**
			JAN 04, 1985
/@/		/15MG/5ML;6.25MG/5ML/	/N88864/001/
			/JAN/04,/1985/

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	**50MG/ML**	**N16730 002**

DEXTROTHYROXINE SODIUM

TABLET; ORAL

	CHOLOXIN			
	+ BOOTS	4MG	N12302 004	
	/+/	/6MG/	/N12302/006/	
		/4MG/	/N12302/004/	
	@	6MG	N12302 006	

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

	CARDIOGRAFIN			
>ADD>	@ BRACCO	85%	N11620 002	
>DLT>	/@/SQUIBB/	/85%/	/N11620/002/	

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

	SINOGRAFIN			
>ADD>	BRACCO	52.7%;26.8%	N11324 002	
>DLT>	/SQUIBB/	/52.7%;26.8%/	/N11324/002/	

DICLOXACILLIN SODIUM

CAPSULE; ORAL

	DYNAPEN			
>ADD>	**AB** APOTHECON	**EQ 500MG BASE**	**N61454 003**	

DICUMAROL

TABLET; ORAL

	DICUMAROL			
>ADD>	+ ABBOTT	25MG	N05545 003	
>DLT>		/25MG/	/N05545/003/	

DIENESTROL

CREAM; VAGINAL

	/**ESTRAGUARD**/			
/AT/	/SOLVAY/	/**0.01%**/	/N84436/001/	
	@ SOLVAY	0.01%	N84436 001	

DIETHYLSTILBESTROL

TABLET; ORAL

	DIETHYLSTILBESTROL			
/BP/	/LILLY/	/1MG/	/N04041/004/	
/BP/+/		/5MG/	/N04041/005/	
	+ LILLY	5MG	N04041 005	
		1MG	N04041 004	
	STILBESTROL			
/BP/	/TABLICAPS/	/1MG/	/N83002/001/	
/BP/		/5MG/	/N83006/001/	
	@ TABLICAPS	1MG	N83002 001	
	@	5MG	N83006 001	

TABLET, DELAYED RELEASE; ORAL

	/STILBESTROL/			
/BE/	/TABLICAPS/	/0.5MG/	/N83003/001/	
/BE/		/1MG/	/N83005/001/	
/BE/		/5MG/	/N83007/001/	
	@ TABLICAPS	0.5MG	N83003 001	
	@	1MG	N83005 001	
	@	5MG	N83007 001	
	/STILBETIN/			
/BE/	/SQUIBB/	/0.5MG/	/N04056/012/	
/BE/		/1MG/	/N04056/013/	
/BE/		/5MG/	/N04056/014/	
	@ SQUIBB	0.5MG	N04056 012	
	@	1MG	N04056 013	
	@	5MG	N04056 014	

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

	DILTIAZEM HCL			
AB	NOVOPHARM	**30MG**	**N74084 001**	
			FEB 25, 1994	
AB		**60MG**	**N74084 002**	
			FEB 25, 1994	

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIPHENHYDRAMINE HCL			
/**AA**/	/LANNETT/	/**25MG**/	/N80868/001/	
/**AA**/		/**50MG**/	/N80868/002/	
	@ LANNETT	25MG	N80868 001	
	@	50MG	N80868 002	
>DLT>/**AA**/	/ROXANE/	/**50MG**/	/N80635/001/	
>ADD>	@ ROXANE	50MG	N80635 001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DIPIVEFRIN HCL

AT	ALCON	**0.1%**	**N73636 001**	JUN 30, 1994

PROPINE

AT	+ ALLERGAN	**0.1%**	**N18239 001**	

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	**EQ 400MG BASE/100ML**	**N20201 006**	JUL 07, 1994
AP	+ BAXTER	**EQ 400MG BASE/100ML**	**N20255 005**	OCT 19, 1993

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

	+ GENDERM	5%	N20126 001	APR 01, 1994

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

/**AP**//+//ADRIA/	/**200MG/100ML**/	/N50629/002/	/MAY/03,/1988/
/**AP**/	/**200MG/100ML**/	/N63165/002/	/JAN/30,/1991/
+ ADRIA	200MG/100ML	N50629 002	MAY 03, 1988
	200MG/100ML	N63165 002	JAN 30, 1991

ENFLURANE

LIQUID; INHALATION

ENFLURANE

AN	INHALON	**99.9%**	**N74396 001**	JUL 29, 1994

ERGOCALCIFEROL

CAPSULE; ORAL

/DELTALIN/

/**AA**/	/LILLY/	/**50,000 IU**/	/N80884/001/
	@ LILLY	50,000 IU	N80884 001

VITAMIN D

/**AA**/	/LANNETT/	/**50,000 IU**/	/N80825/001/
	@ LANNETT	50,000 IU	N80825 001
/**AA**/	/WEST/WARD/	/**50,000 IU**/	/N83102/001/
	@ WEST WARD PHARM	50,000 IU	N83102 001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

/**AB**/	/PARKE/DAVIS/	/**250MG**/	/N62546/001/ /JUL/25,/1985/
	@ PARKE DAVIS	250MG	N62546 001 JUL 25, 1985

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT	BAUSCH AND LOMB	**0.5%**	**N64067 001** JUL 29, 1994
/**AT**/	/FOUGERA/	/**5MG/GM**/	/N62447/001/ /SEP/26,/1983/
AT	FOUGERA	**0.5%**	**N62447 001** SEP 26, 1983

ILOTYCIN

/**AT**//+//DISTA/		/**5MG/GM**/	/N50368/001/
AT	+ DISTA	**0.5%**	**N50368 001**

SOLUTION; TOPICAL

ERYTHROMYCIN

/**AT**/	/BARRE/	/**2%**/	/N62957/001/ /JUL/21,/1988/
	@ BARRE	2%	N62957 001 JUL 21, 1988
AT	BAUSCH AND LOMB	**2%**	**N64039 001** JAN 27, 1994
/**AT**/	/PHARMAFAIR/	/**2%**/	/N62616/001/ /JUL/25,/1985/
	@ PHARMAFAIR	2%	N62616 001 JUL 25, 1985

ERYTHROMYCIN

TABLET, COATED PARTICLES; ORAL
PCE
+ ABBOTT 333MG N50611 001
SEP 09, 1986
/333MG/ /N50611/001/
/SEP/09,/1986/

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL
ERYTHROMYCIN ETHYLSUCCINATE
/AB/ /DISTA/ /EQ 200MG BASE/5ML/ /N62177/001/
/AB/ /EQ 400MG BASE/5ML/ /N62177/002/
@ DISTA EQ 200MG BASE/5ML N62177 001
@ EQ 400MG BASE/5ML N62177 002
/AB/ /PHARMAFAIR/ /EQ 200MG BASE/5ML/ /N62559/001/
/MAR/15,/1985/
>_DLT_>/AB/ /EQ 400MG BASE/5ML/ /N62558/001/
>_DLT_> /MAR/15,/1985/
@ PHARMAFAIR EQ 200MG BASE/5ML N62559 001
MAR 15, 1985
>_ADD_> @ EQ 400MG BASE/5ML N62558 001
>_ADD_> MAR 15, 1985

TABLET; ORAL
E.E.S. 400
/AB//+//ABBOTT/ /EQ 400MG BASE/ /N61905/001/
/AB/ /EQ 400MG BASE/ /N61905/002/
/AUG/12,/1982/
AB + ABBOTT EQ 400MG BASE N61905 002
AUG 12, 1982
@ EQ 400MG BASE N61905 001

ERYTHROMYCIN STEARATE

TABLET; ORAL
/ERYPAR/
/AB/ /PARKE/DAVIS/ /EQ 250MG BASE/ /N62322/001/
ERYPAR
@ WARNER CHILCOTT EQ 250MG BASE N62322 001

ERYTHROMYCIN STEARATE
/AB/ /PUREPAC/ /EQ 250MG BASE/ /N61743/001/
@ PUREPAC PHARM EQ 250MG BASE N61743 001

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
/DELADUMONE/
/AO//+//SQUIBB/ /4MG/ML;90MG/ML/ /N09545/001/
@ SQUIBB 4MG/ML;90MG/ML N09545 001

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE
/AO/ /STERIS/ /4MG/ML;90MG/ML/ /N85865/001/
+ STERIS 4MG/ML;90MG/ML N85865 001

ESTROGENS, ESTERIFIED

TABLET; ORAL
ESTRATAB
/BS/ /SOLVAY/ /0.625MG/ /N83209/001/
BS + SOLVAY 0.625MG N83209 001
/BS/ /2.5MG/ /N83857/001/
BS + 2.5MG N83857 001
MENEST
/BS/+//SMITHKLINE/BEECHAM/ /0.625MG/ /N84948/001/
BS SMITHKLINE BEECHAM 0.625MG N84948 001
/BS/+/ /2.5MG/ /N84949/001/
BS 2.5MG N84949 001

ESTRONE

INJECTABLE; INJECTION
ESTRONE
/BP/ /STERIS/ /2MG/ML/ /N83397/001/
@ STERIS 2MG/ML N83397 001

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL
MYAMBUTOL
+ LEDERLE 400MG N16320 003
/+/ /500MG/ /N16320/004/
/200MG/ /N16320/002/
@ 200MG N16320 002
/400MG/ /N16320/003/
@ 500MG N16320 004

ETHINAMATE

/CAPSULE;/ORAL/
/VALMID/
/DISTA/ /500MG/ /N09750/001/
@ DISTA 500MG N09750 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

/TABLET;/ORAL-28/
/NORQUEST/FE/
/+//SYNTEX/ /0.035MG;75MG;1MG/ /N18926/001/
/JUL/18,/1986/
@ SYNTEX 0.035MG;75MG;1MG N18926 001
JUL 18, 1986

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)
/WATSON/ /0.035MG;0.5MG/AND/1MG/ /N71041/001/
/SEP/24,/1991/
AB WATSON LABS **0.035MG;0.5MG AND 1MG** **N71041 001**
SEP 24, 1991

ORTHO-NOVUM 7/14-21
AB + JOHNSON RW **0.035MG;0.5MG AND 1MG** **N19004 001**
APR 04, 1984
/@/ /0.035MG;0.5MG/AND/1MG/ /N19004/001/
/APR/04,/1984/

TABLET; ORAL-28
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)
/WATSON/ /0.035MG;0.5MG/AND/1MG/ /N71042/001/
/SEP/24,/1991/
AB WATSON LABS **0.035MG;0.5MG AND 1MG** **N71042 001**
SEP 24, 1991

ORTHO-NOVUM 7/14-28
AB + JOHNSON RW **0.035MG;0.5MG AND 1MG** **N19004 002**
APR 04, 1984
/@/ /0.035MG;0.5MG/AND/1MG/ /N19004/002/
/APR/04,/1984/

ETODOLAC

TABLET; ORAL
LODINE
+ WYETH AYERST 400MG N18922 004
JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE
AP GENSIA **20MG/ML** **N74284 001**
FEB 10, 1994

ETOPOSIDE

INJECTABLE; INJECTION
VEPESID
AP + BRISTOL **20MG/ML** **N18768 001**
NOV 10, 1983

FAMCICLOVIR

TABLET; ORAL
FAMVIR
+ SMITHKLINE BEECHAM 500MG N20363 002
JUN 29, 1994

FAMOTIDINE

INJECTABLE; INJECTION
PEPCID IN PLASTIC CONTAINER
+ MERCK 0.4MG/ML N20249 001
FEB 18, 1994

FLUCONAZOLE

TABLET; ORAL
DIFLUCAN
/+//PFIZER/ /50MG/ /N19949/001/
/JAN/29,/1990/
/+/ /100MG/ /N19949/002/
/JAN/29,/1990/
PFIZER 50MG N19949 001
JAN 29, 1990
100MG N19949 002
JAN 29, 1990
150MG N20322 001
JUN 30, 1994

>ADD> FLUDEOXYGLUCOSE, F-18

>ADD> INJECTABLE; INJECTION
>ADD> FLUDEOXYGLUCOSE F 18
>ADD> + DOWNSTATE CLINCL 6.8-35.7mCi/ML N20306 001
>ADD> AUG 19, 1994

FLUMAZENIL

INJECTABLE; INJECTION
/MAZICON/
/+//ROCHE/ /0.1MG/ /N20073/001/ /DEC/20,/1991/

ROMAZICON
+ ROCHE 0.1MG/ML N20073 001 DEC 20, 1991

FLUOCINOLONE ACETONIDE

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
/AT/ /PHARMAFAIR/ /**0.01%**/ /N88449/001/ /FEB/08,/1984/

@ PHARMAFAIR 0.01% N88449 001 FEB 08, 1984

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE
/B*/ /CLAY/PARK/ /0.05%/ /N71790/001/ /JUL/13,/1988/

@ CLAY PARK 0.05% N71790 001 JUL 13, 1988

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL
/AP//+//ADRIA/ /**50MG/ML**/
/AP/ /**50MG/ML**/ /N17959/001/ /N40023/001/ /OCT/18,/1991/

AP + PHARMACIA **50MG/ML** **N40023 001** OCT 18, 1991

@ 50MG/ML N17959 001

FLURANDRENOLIDE

CREAM; TOPICAL
CORDRAN SP
/+//DISTA/ /0.025%/ /N12806/003/ /+/ /0.05%/ /N12806/002/
+ LILLY 0.025% N12806 003
+ 0.05% N12806 002

FLURANDRENOLIDE

LOTION; TOPICAL
CORDRAN
/**AT**//+//DISTA/ /**0.05%**/ /N13790/001/
AT + LILLY **0.05%** **N13790 001**

OINTMENT; TOPICAL
CORDRAN
/+//DISTA/ /0.025%/ /N12806/004/
/+/ /0.05%/ /N12806/001/
+ LILLY 0.025% N12806 004
+ 0.05% N12806 001

TAPE; TOPICAL
CORDRAN
/+//DISTA/ /0.004MG/SQ/CM/ /N16455/001/
+ LILLY 0.004MG/SQ CM N16455 001

FLURBIPROFEN

TABLET; ORAL
ANSAID
AB UPJOHN **50MG** **N18766 002** OCT 31, 1988
AB + **100MG** **N18766 003** OCT 31, 1988

FLURBIPROFEN
AB MYLAN **50MG** **N74358 001** JUN 20, 1994
AB **100MG** **N74358 002** JUN 20, 1994

FOLIC ACID

TABLET; ORAL
FOLIC ACID
/**AA**/ /LANNETT/ /**1MG**/ /N80816/001/
@ LANNETT 1MG N80816 001
/**AA**/ /PUREPAC/ /**1MG**/ /N80784/001/
@ PUREPAC 1MG N80784 001

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE
AP MARSAM **10MG/ML** **N74017 001** JUN 30, 1994

FUROSEMIDE

INJECTABLE; INJECTION

	FUROSEMIDE			
/AP/	/ORGANON/	/10MG/ML/	/N70017/001/ /DEC/15,/1986/	
	@ ORGANON	10MG/ML	N70017 001 DEC 15, 1986	
/AP/	/WARNER/CHILCOTT/	/10MG/ML/	/N18420/001/ /FEB/26,/1982/	
	@ WARNER CHILCOTT	10MG/ML	N18420 001 FEB 26, 1982	

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION

	GALLIUM CITRATE GA 67		
BS	DUPONT	2MCI/ML	N17478 001
/BS/	/DUPONT/MERCK/	/2MCI/ML/	/N17478/001/

GEMFIBROZIL

TABLET; ORAL

		GEMFIBROZIL		
>_ADD_>	**AB**	PUREPAC PHARM	**600MG**	**N74360 001** AUG 31, 1994
>_ADD_>				

GENTAMICIN SULFATE

CREAM; TOPICAL

	GARAMYCIN		
/AT//+//SCHERING/		/EQ 1MG BASE/GM/	/N60462/001/
AT +	SCHERING	EQ 0.1% BASE	**N60462 001**
	GENTAFAIR		
/AT/	/PHARMAFAIR/	/EQ 0.1% BASE/	/N62458/001/ /SEP/01,/1983/
	@ PHARMAFAIR	EQ 0.1% BASE	N62458 001 SEP 01, 1983
	GENTAMICIN		
/AT/	/CLAY/PARK/	/EQ 1MG BASE/GM/	/N62307/001/
AT	CLAY PARK	EQ 0.1% BASE	**N62307 001**
	GENTAMICIN SULFATE		
AT	BAUSCH AND LOMB	EQ 0.1% BASE	**N64056 001** APR 29, 1994
/AT/	/FOUGERA/	/EQ 1MG BASE/GM/	/N62531/001/ /JUL/05,/1984/
AT	FOUGERA	EQ 0.1% BASE	**N62531 001** JUL 05, 1984

GENTAMICIN SULFATE

CREAM; TOPICAL

	GENTAMICIN SULFATE		
/AT/	/NMC/	/EQ 1MG BASE/GM/	/N62471/001/ /SEP/27,/1983/
AT	NMC	EQ 0.1% BASE	**N62471 001** SEP 27, 1983
/AT/	/THAMES/	/EQ 1MG BASE/GM/	/N62427/001/ /MAY/26,/1983/
AT	THAMES	EQ 0.1% BASE	**N62427 001** MAY 26, 1983

INJECTABLE; INJECTION

	APOGEN		
AP	KING PHARMS	EQ 10MG BASE/ML	**N62289 001**
AP		EQ 40MG BASE/ML	**N62289 002**
/AP/	/SMITHKLINE/BEECHAM/	/EQ 10MG BASE/ML/	/N62289/001/
/AP/		/EQ 40MG BASE/ML/	/N62289/002/
	GARAMYCIN		
/AP//+//SCHERING/		/EQ 2MG BASE/ML/	/N50505/001/

INJECTABLE; INTRATHECAL

GARAMYCIN		
+	SCHERING	EQ 2MG BASE/ML	N50505 001

OINTMENT; OPHTHALMIC

	GARAMYCIN		
/AT//+//SCHERING/		/EQ 3MG BASE/GM/	/N50425/001/
AT +	SCHERING	EQ 0.3% BASE	**N50425 001**
	GENTACIDIN		
/AT/	/IOLAB/	/EQ 3MG BASE/GM/	/N62501/001/ /JUL/26,/1984/
AT	IOLAB	EQ 0.3% BASE	**N62501 001** JUL 26, 1984

OINTMENT; TOPICAL

	GARAMYCIN		
/AT//+//SCHERING/		/EQ 1MG BASE/GM/	/N60463/001/
AT +	SCHERING	EQ 0.1% BASE	**N60463 001**
	GENTAFAIR		
/AT/	/PHARMAFAIR/	/EQ 0.1% BASE/	/N62444/001/ /MAY/26,/1983/
	@ PHARMAFAIR	EQ 0.1% BASE	N62444 001 MAY 26, 1983

GENTAMICIN SULFATE

OINTMENT; TOPICAL

	GENTAMICIN		
/AT/	/CLAY/PARK/	/EQ 1MG BASE/GM/	/N62351/001/ /FEB/18,/1982/
AT	CLAY PARK	EQ 0.1% BASE	**N62351 001** FEB 18, 1982
	GENTAMICIN SULFATE		
AT	BAUSCH AND LOMB	EQ 0.1% BASE	**N64054 001** APR 29, 1994
/AT/	/FOUGERA/	/EQ 1MG BASE/GM/	/N62533/001/ /OCT/05,/1984/
AT	FOUGERA	EQ 0.1% BASE	**N62533 001** OCT 05, 1984
/AT/	/NMC/	/EQ 1MG BASE/GM/	/N62496/001/ /MAR/14,/1984/
AT	NMC	EQ 0.1% BASE	**N62496 001** MAR 14, 1984
/AT/	/PHARMADERM/	/EQ 1MG BASE/GM/	/N62534/001/ /OCT/10,/1984/
AT	PHARMADERM	EQ 0.1% BASE	**N62534 001** OCT 10, 1984
/AT/	/THAMES/	/EQ 1MG BASE/GM/	/N62477/001/ /DEC/23,/1983/
AT	THAMES	EQ 0.1% BASE	**N62477 001** DEC 23, 1983

SOLUTION/DROPS; OPHTHALMIC

	GARAMYCIN		
/AT//+/	/SCHERING/	/EQ 3MG BASE/ML/	/N50039/002/
AT +	SCHERING	EQ 0.3% BASE	**N50039 002**
	GENOPTIC		
/AT/	/ALLERGAN/	/EQ 3MG BASE/ML/	/N62452/001/ /OCT/10,/1984/
AT	ALLERGAN	EQ 0.3% BASE	**N62452 001** OCT 10, 1984
	GENTACIDIN		
/AT/	/IOLAB/	/EQ 3MG BASE/ML/	/N62480/001/ /MAR/30,/1984/
AT	IOLAB	EQ 0.3% BASE	**N62480 001** MAR 30, 1984
>DLT>	**/GENTAFAIR/**		
>DLT>/AT/	/PHARMAFAIR/	/EQ 0.3% BASE/	/N62440/001/ /MAY/03,/1983/
>DLT>			
>ADD>	@ PHARMAFAIR	EQ 0.3% BASE	N62440 001 MAY 03, 1983
>ADD>			

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

	GENTAMICIN SULFATE		
/AT/	/AKORN/	/EQ 3MG BASE/ML/	/N62635/001/ /JAN/08,/1987/
AT	AKORN	EQ 0.3% BASE	**N62635 001** JAN 08, 1987
AT	BAUSCH AND LOMB	EQ 0.3% BASE	**N64048 001** MAY 11, 1994
/AT/	/STERIS/	/EQ 3MG BASE/ML/	/N62523/001/ /NOV/25,/1985/
AT	STERIS	EQ 0.3% BASE	**N62523 001** NOV 25, 1985

GLIPIZIDE

TABLET; ORAL

	GLIPIZIDE		
AB	MYLAN	5MG	**N74226 001** MAY 10, 1994
AB		10MG	**N74226 002** MAY 10, 1994
	GLUCOTROL		
AB	PFIZER	5MG	**N17783 001** MAY 08, 1984
AB +		10MG	**N17783 002** MAY 08, 1984

TABLET, EXTENDED RELEASE; ORAL

	GLUCOTROL XL		
+	PFIZER	5MG	N20329 001 APR 26, 1994
+		10MG	N20329 002 APR 26, 1994

GLUTETHIMIDE

TABLET; ORAL

	GLUTETHIMIDE		
/AA/	/HALSEY/	/250MG/	/N89458/001/ /OCT/10,/1986/
	HALSEY	250MG	**N89458 001** OCT 10, 1986
/AA/	/LANNETT/	/250MG/	/N83475/001/
/AA/		/500MG/	/N85571/001/
	@ LANNETT	250MG	N83475 001
	@	500MG	N85571 001

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

/AP/	/FUJISAWA/	/0.2MG/ML/	/N88475/001/ /JUN/12,/1984/
	@ FUJISAWA	0.2MG/ML	N88475 001 JUN 12, 1984

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

/AP/	/FUJISAWA/	/5,000 UNITS/VIAL/	/N17067/001/
/AP/		/20,000 UNITS/VIAL/	/N17067/003/
	@ FUJISAWA	5,000 UNITS/VIAL	N17067 001
	@	20,000 UNITS/VIAL	N17067 003

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
/NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN/

/AT/	/PHARMAFAIR/	/0.025MG/ML;EQ 1.75MG BASE/ML;/ /10,000 UNITS/ML/	/N62383/001/ /AUG/31,/1982/
	@ PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62383 001 AUG 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION
KYTRIL

>_ADD_>	+	SMITHKLINE BEECHAM	EQ 1MG BASE/ML	N20239 002 MAR 11, 1994
>_ADD_>				
>_DLT_>	/+/		/EQ/3MG/BASE/ML/	/N20239/001/ /DEC/29,/1993/
>_DLT_>				
>_ADD_>	@		EQ 3MG BASE/ML	N20239 001 DEC 29, 1993
>_ADD_>				

GUANABENZ ACETATE

TABLET; ORAL
GUANABENZ ACETATE

AB	COPLEY PHARM	EQ 4MG BASE	N74267 001 JUN 01, 1994
AB		EQ 8MG BASE	N74267 002 JUN 01, 1994

GUANABENZ ACETATE

TABLET; ORAL
GUANABENZ ACETATE

AB	WATSON LABS	EQ 4MG BASE	N74025 001 FEB 28, 1994
AB		EQ 8MG BASE	N74025 002 FEB 28, 1994

WYTENSIN

AB	WYETH AYERST	EQ 4MG BASE	N18587 001 SEP 07, 1982
AB	+	EQ 8MG BASE	N18587 002 SEP 07, 1982

HEPARIN CALCIUM

INJECTABLE; INJECTION
CALCIPARINE

+ CHOAY	25,000 UNITS/ML	N18237 001
/+//DUPONT/	/25,000/UNITS/ML/	/N18237/001/

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

/BP/	/DANBURY/PHARMA/	/25MG;15MG;0.1MG/	/N87556/001/
	@ DANBURY PHARMA	25MG;15MG;0.1MG	N87556 001

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

/AB/	/ZENITH/	/50MG/	/N84658/001/
	@ ZENITH	50MG	N84658 001

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

>_DLT_>	/TABLET;/ORAL/		
>_DLT_>	/NORMOZIDE/		
>_DLT_>	/+//SCHERING/	/25MG;300MG/	/N19046/003/ /APR/06,/1987/
>_DLT_>			
>_DLT_>		/25MG;100MG/	/N19046/001/ /APR/06,/1987/
>_DLT_>			
>_DLT_>		/25MG;200MG/	/N19046/002/ /APR/06,/1987/
>_DLT_>			

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

>_DLT_> /TABLET;/ORAL/
>_DLT_> /NORMOZIDE/
>_ADD_> @ SCHERING 25MG;100MG N19046 001 APR 06, 1987
>_ADD_>
>_ADD_> @ 25MG;200MG N19046 002 APR 06, 1987
>_ADD_>
>_ADD_> @ 25MG;300MG N19046 003 APR 06, 1987
>_ADD_>

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
HYDROCHLOROTHIAZIDE W/ RESERPINE
/BP/ /ROXANE/ /50MG;0.125MG/ /N84603/001/
@ ROXANE 50MG;0.125MG N84603 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
DYAZIDE
/**AB**//+//SMITHKLINE/BEECHAM/ /**25MG**;**50MG**/ /N16042/002/
SMITHKLINE BEECHAM 25MG;37.5MG N16042 003 MAR 03, 1994
@ 25MG;50MG N16042 002
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
/**AB**/ /GENEVA/PHARMS/ /**25MG**;**50MG**/ /N73191/001/ /JUL/31,/1991/
+ GENEVA PHARMS 25MG;50MG N73191 001 JUL 31, 1991

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE
/**AT**/ /LEMMON/ /**1%**/ /N85191/001/
@ LEMMON 1% N85191 001
/**AT**/ /PHARMAFAIR/ /**1%**/ /N87838/001/ /JUL/28,/1982/
@ PHARMAFAIR 1% N87838 001 JUL 28, 1982

ENEMA; RECTAL
CORTENEMA
AT + SOLVAY **100MG/60ML** **N16199 001**
HYDROCORTISONE
AT COPLEY **100MG/60ML** **N74171 001** MAY 27, 1994

HYDROCORTISONE

GEL; TOPICAL
/NUTRACORT/
/**AT**//+//GALDERMA/ /**1%**/ /N84698/001/
@ GALDERMA 1% N84698 001

PENECORT
/**AT**/ /ALLERGAN/HERBERT/ /**1%**/ /N88215/001/ /JUN/06,/1984/
+ ALLERGAN HERBERT 1% N88215 001 JUN 06, 1984

LOTION; TOPICAL
HYDROCORTISONE
/**AT**/ /CLAY/PARK/ /**1%**/ /N85663/001/
@ CLAY PARK 1% N85663 001

OINTMENT; TOPICAL
HYDROCORTISONE
/**AT**/ /CLAY/PARK/ /**1%**/ /N85028/001/
@ CLAY PARK 1% N85028 001

TABLET; ORAL
HYDROCORTISONE
/BP/ /DANBURY/PHARMA/ /20MG/ /N80355/001/
@ DANBURY PHARMA 20MG N80355 001
>_DLT_> /BP/ /INWOOD/ /20MG/ /N80732/001/
>_ADD_> @ INWOOD LABS 20MG N80732 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
/NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE/
/**AT**/ /PHARMAFAIR/ /**1%**;**EQ 3.5MG BASE/ML**;/ /**10,000 UNITS/ML**/ /N62394/001/ /SEP/29,/1982/
@ PHARMAFAIR 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62394 001 SEP 29, 1982

SUSPENSION; OTIC
/OTICAIR/
/**AT**/ /PHARMAFAIR/ /**1%**;**EQ 3.5MG BASE/ML**;/ /**10,000 UNITS/ML**/ /N62399/001/ /NOV/18,/1982/
@ PHARMAFAIR 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62399 001 NOV 18, 1982

HYDROCORTISONE ACETATE

CREAM; TOPICAL
HYDROCORTISONE ACETATE

/AT/	/PARKE/DAVIS/	/1%/	/N89914/001/ /JAN/03,/1989/		
	@ PARKE DAVIS	1%	N89914 001 JAN 03, 1989		

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE

/BP/	/STERIS/	/50MG/ML/	/N85214/001/		
	@ STERIS	50MG/ML	N85214 001		

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID

/+//BROCADES/PHARMA/		/0.1%/	/N18514/001/ /MAR/31,/1982/		
+	YAMANOUCHI	0.1%	N18514 001 MAR 31, 1982	>_ADD_> >_ADD_>	

OINTMENT; TOPICAL
LOCOID

/@/BROCADES/PHARMA/		/0.1%/	/N18652/001/ /OCT/29,/1982/		
	@ YAMANOUCHI	0.1%	N18652 001 OCT 29, 1982		

SOLUTION; TOPICAL
LOCOID

/+//BROCADES/PHARMA/		/0.1%/	/N19116/001/ /FEB/25,/1987/		
+	YAMANOUCHI	0.1%	N19116 001 FEB 25, 1987		

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT

/AP/	/ABBOTT/	/EQ 250MG BASE/VIAL/	/N89578/001/ /APR/11,/1989/		
/AP/		/EQ 500MG BASE/VIAL/	/N89579/001/ /APR/11,/1989/		
/AP/		/EQ 1GM BASE/VIAL/	/N89580/001/ /APR/11,/1989/		
	@ ABBOTT	EQ 250MG BASE/VIAL	N89578 001 APR 11, 1989		
	@	EQ 500MG BASE/VIAL	N89579 001 APR 11, 1989		
	@	EQ 1GM BASE/VIAL	N89580 001 APR 11, 1989		

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
DILAUDID-HP

+	KNOLL PHARM	250MG/VIAL	N19034 002 AUG 04, 1994		

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION
/DELALUTIN/

/AO//+//SQUIBB/		/125MG/ML/	/N10347/004/		
/AO/		/125MG/ML/	/N16911/001/		
/AO//+/		/250MG/ML/	/N10347/002/		
/AO/		/250MG/ML/	/N16911/002/		
	@ SQUIBB	125MG/ML	N10347 004		
	@	125MG/ML	N16911 001		
	@	250MG/ML	N10347 002		
	@	250MG/ML	N16911 002		

HYDROXYPROGESTERONE CAPROATE

/AO/	/STERIS/	/125MG/ML/	/N17439/001/		
AO	+ STERIS	125MG/ML	N17439 001		
/AO/		/250MG/ML/	/N17439/002/		
	+	250MG/ML	N17439 002		

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

/AP/	/SMITH/NEPHEW/SOLOPAK/	25MG/ML/	/N87591/001/		
/AP/		/50MG/ML/	/N87593/001/		
/AP/		/50MG/ML/	/N87595/001/		

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP	SOLOPAK	25MG/ML	N87591 001
AP		50MG/ML	N87593 001
AP		50MG/ML	N87595 001
	/ORGATRAX/		
/AP/	/ORGANON/	/25MG/ML/	/N87014/001/
/AP/		/50MG/ML/	/N87014/002/
	@ ORGANON	25MG/ML	N87014 001
	@	50MG/ML	N87014 002

TABLET; ORAL
HYDROXYZINE HCL

AB	ROYCE	10MG	N81149 001 MAR 18, 1994
AB		25MG	N81150 001 MAR 18, 1994
AB		50MG	N81151 001 MAR 18, 1994

IMIGLUCERASE

INJECTABLE; INJECTION
CEREZYME

+	GENZYME	200 UNITS/VIAL	N20367 001 MAY 23, 1994

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION
OCTREOSCAN

	MALLINCKRODT	3mCi/ML	N20314 001 JUN 02, 1994

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

/AB/	/CHELSEA/LABS/	/25MG/	/N18690/001/ /JUL/31,/1984/
/AB/		/50MG/	/N18690/002/ /JUL/31,/1984/
	@ CHELSEA LABS	25MG	N18690 001 JUL 31, 1984
	@	50MG	N18690 002 JUL 31, 1984

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN R

+	LILLY	500 UNITS/ML	N18780 004 MAR 31, 1994

INVERT SUGAR

/INJECTABLE;/INJECTION/
/TRAVERT/10%/IN/PLASTIC/CONTAINER/

/BAXTER/	/10GM/100ML/	/N16717/001/
@ BAXTER	10GM/100ML	N16717 001

IOBENGUANE SULFATE I 131

INJECTABLE; INJECTION
IOBENGUANE SULFATE I 131

CIS	2.3mCi/ML	N20084 001 MAR 25, 1994

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION
RENOVUE-65

>ADD>	+	BRACCO	65%	N17902 001
>DLT>	/+//SQUIBB/		/65%/	/N17902/001/

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION
CHOLOGRAFIN MEGLUMINE

>ADD>	+	BRACCO	10.3%	N09321 007
>ADD>	+		52%	N09321 003
>DLT>	/+//SQUIBB/		/10.3%/	/N09321/007/
>DLT>	/+/		/52%/	/N09321/003/

IODIPAMIDE SODIUM

INJECTABLE; INJECTION
CHOLOGRAFIN SODIUM

>ADD>	@	BRACCO	20%	N09321 001
>DLT>	/@/SQUIBB/		/20%/	/N09321/001/

IODOHIPPURATE SODIUM, I-123

/INJECTABLE;/INJECTION/
/NEPHROFLOW/

	/MEDI/PHYSICS/	/1MCI/ML/	/N18289/001/
			/DEC/28,/1984/
	@ MEDI PHYSICS	1MCI/ML	N18289 001
			DEC 28, 1984

IODOXAMATE MEGLUMINE

INJECTABLE; INJECTION
CHOLOVUE

>ADD>	@ BRACCO	9.9%	N18077 001
>ADD>	@	40.3%	N18076 001
>DLT>	/@/SQUIBB/	/9.9%/	/N18077/001/
>DLT>	/@/	/40.3%/	/N18076/001/

IOHEXOL

SOLUTION; URETHRAL
OMNIPAQUE 70

>ADD>	+ STERLING WINTHROP	15.1%	N18956 007
>ADD>			JUN 01, 1994

IPODATE CALCIUM

GRANULE; ORAL
ORAGRAFIN CALCIUM

>ADD>	BRACCO	3GM/PACKET	N12968 001
>DLT>	/SQUIBB/	/3GM/PACKET/	/N12968/001/

IPODATE SODIUM

CAPSULE; ORAL
ORAGRAFIN SODIUM

>ADD>	**AA**	BRACCO	**500MG**	**N12967 001**
>DLT>	/**AA**/	/SQUIBB/	/**500MG**/	/N12967/001/

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL
RIFATER

	+ MARION MERRELL DOW	50MG;300MG;120MG	N50705 001
			MAY 31, 1994

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION
ISUPREL

/+//STERLING/WINTHROP/	/0.113MG/INH/	/N11178/001/
+ STERLING WINTHROP	0.131MG/INH	N11178 001

ISOSORBIDE MONONITRATE

TABLET; ORAL
ISMO

>ADD>	**AB**	+ WYETH	**20MG**	**N19091 001**
>ADD>				DEC 30, 1991
>DLT>	/BX/+/		/20MG/	/N19091/001/
>DLT>				/DEC/30,/1991/

MONOKET

>ADD>	**AB**	SCHWARZ PHARMA	**20MG**	**N20215 001**
>ADD>				JUN 30, 1993
>DLT>	/BX/		/20MG/	/N20215/001/
>DLT>				/JUN/30,/1993/

ISRADIPINE

CAPSULE; ORAL
DYNACIRC

+ SANDOZ	5MG	N19546 002
		DEC 20, 1990
	/5MG/	/N19546/002/
		/DEC/20,/1990/

TABLET, EXTENDED RELEASE; ORAL
DYNACIRC CR

+ SANDOZ	5MG	N20336 001
		JUN 01, 1994
+	10MG	N20336 002
		JUN 01, 1994

KANAMYCIN SULFATE

CAPSULE; ORAL
KANTREX

/+//APOTHECON/	/EQ/500MG/BASE/	/N61911/001/
+ APOTHECON	EQ 500MG BASE	N62726 001
		MAR 06, 1987
@	EQ 500MG BASE	N60516 001
@	EQ 500MG BASE	N61911 001
	/EQ/500MG/BASE/	/N62726/001/
		/MAR/06,/1987/
/**AB**//+//BRISTOL/	/**EQ 500MG BASE**/	/N60516/001/

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANTREX		
/AP//+//APOTHECON/	/EQ 75MG BASE/2ML/	/N61655/003/	
/AP/	/EQ 75MG BASE/2ML/	/N61901/003/	
AP + APOTHECON	EQ 75MG BASE/2ML	N61901 003	
/AP//+/	/EQ 500MG BASE/2ML/	/N61655/001/	
/AP/	/EQ 500MG BASE/2ML/	/N61901/001/	
AP +	EQ 500MG BASE/2ML	N61901 001	
/AP//+/	/EQ 1GM BASE/3ML/	/N61655/002/	
/AP/	/EQ 1GM BASE/3ML/	/N61901/002/	
AP +	EQ 1GM BASE/3ML	N61901 002	
@	EQ 75MG BASE/2ML	N61655 003	
@	EQ 75MG BASE/2ML	N62564 001	SEP 21, 1984
@	EQ 500MG BASE/2ML	N61655 001	
@	EQ 500MG BASE/2ML	N62564 002	SEP 21, 1984
@	EQ 1GM BASE/3ML	N61655 002	
@	EQ 1GM BASE/3ML	N62564 003	SEP 21, 1984
/AP/ /BRISTOL/	/EQ 75MG BASE/2ML/	/N62564/001/	/SEP/21,/1984/
/AP/	/EQ 500MG BASE/2ML/	/N62564/002/	/SEP/21,/1984/
/AP/	/EQ 1GM BASE/3ML/	/N62564/003/	/SEP/21,/1984/
KLEBCIL			
@ KING PHARMS	EQ 75MG BASE/2ML	N62170 001	
@	EQ 500MG BASE/2ML	N62170 002	
@	EQ 1GM BASE/3ML	N62170 003	
/@/SMITHKLINE/BEECHAM/	/EQ/75MG/BASE/2ML/	/N62170/001/	
/@/	/EQ/500MG/BASE/2ML/	/N62170/002/	
/@/	/EQ/1GM/BASE/3ML/	/N62170/003/	

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM		
AP ELKINS SINN	EQ 100MG BASE/VIAL	N81224 001	JUN 03, 1994
/+//IMMUNEX/	/EQ/3MG/BASE/ML/	/N08107/001/	
@ IMMUNEX	EQ 3MG BASE/ML	N08107 001	

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	BETAGAN		
AT + ALLERGAN	0.25%	N19814 001	JUN 28, 1989
AT +	0.5%	N19219 002	DEC 19, 1985
	LEVOBUNOLOL HCL		
AT BAUSCH AND LOMB	0.25%	N74307 001	MAR 04, 1994
AT	0.5%	N74326 001	MAR 04, 1994

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	/ARESTOCAINE HCL W/ LEVONORDEFRIN/		
/AP/ /CARLISLE/	/0.05MG/ML;2%/	/N85010/001/	
@ SOLVAY	0.05MG/ML;2%	N85010 001	

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

	MYLOCAINE		
AT PENNEX	4%	N87881 001	NOV 18, 1982
/@/	/4%/	/N87881/001/	/NOV/18,/1982/
	PEDIATRIC LTA KIT		
/AT/ /ABBOTT/	/2%/	/N88572/001/	/JUL/31,/1984/
@ ABBOTT	2%	N88572 001	JUL 31, 1984

LIOTRIX (T4;T3)

TABLET; ORAL

/EUTHROID-0.5/		
/PARKE/DAVIS/	/0.03MG;0.0075MG/	/N16680/001/
@ PARKE DAVIS	0.03MG;0.0075MG	N16680 001
/EUTHROID-1/		
/PARKE/DAVIS/	/0.06MG;0.015MG/	/N16680/002/
@ PARKE DAVIS	0.06MG;0.015MG	N16680 002
/EUTHROID-2/		
/PARKE/DAVIS/	/0.12MG;0.03MG/	/N16680/003/
@ PARKE DAVIS	0.12MG;0.03MG	N16680 003
/EUTHROID-3/		
/+//PARKE/DAVIS/	/0.18MG;0.045MG/	/N16680/004/
@ PARKE DAVIS	0.18MG;0.045MG	N16680 004

LISINOPRIL

TABLET; ORAL

	PRINIVIL			
AB	MERCK	2.5MG	N19558 006	
			JAN 28, 1994	
	ZESTRIL			
AB	ZENECA	2.5MG	N19777 005	
			APR 29, 1993	

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

	/LITHOBID/		
	/+//CIBA/	/300MG/	/N18027/001/
	@ CIBA	300MG	N18027 001

LORAZEPAM

INJECTABLE; INJECTION

	ATIVAN			
AP	+ WYETH AYERST	2MG/ML	N18140 001	
AP	+	4MG/ML	N18140 002	
	LORAZEPAM			
AP	ABBOTT	2MG/ML	N74280 001	
			MAY 27, 1994	
AP		2MG/ML	N74282 001	>ADD>
			MAY 27, 1994	>ADD>
AP		4MG/ML	N74280 002	>DLT>
			MAY 27, 1994	>DLT>
AP		4MG/ML	N74282 002	
			MAY 27, 1994	
AP	STERIS	2MG/ML	N74276 001	
			APR 15, 1994	
AP		4MG/ML	N74276 002	
			APR 15, 1994	
AP	STERLING WINTHROP	2MG/ML	N74243 001	
			APR 12, 1994	
AP		2MG/ML	N74300 001	
			APR 12, 1994	
AP		4MG/ML	N74243 002	
			APR 12, 1994	

LORAZEPAM

TABLET; ORAL

	LORAZEPAM			
/AB/	/WARNER/CHILCOTT/	/1MG/	/N71038/001/	
			/JAN/12,/1988/	
/AB/		/2MG/	/N71039/001/	
			/JAN/12,/1988/	
	@ WARNER CHILCOTT	1MG	N71038 001	
			JAN 12, 1988	
	@	2MG	N71039 001	
			JAN 12, 1988	

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

ABBOTT	4GM/100ML	N20309 001
		JUN 24, 1994
	80MG/ML	N20309 002
		JUN 24, 1994

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

	DEPO-PROVERA			
	+ UPJOHN	150MG/ML	N20246 001	
			OCT 29, 1992	
		/150MG/ML/	/N20246/001/	
			/OCT/29,/1992/	

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	/ARESTOCAINE HCL/		
/AP/	/CARLISLE/	/3%/	/N84777/002/
			/APR/18,/1982/
	@ SOLVAY	3%	N84777 002
			APR 18, 1982

MEPROBAMATE

TABLET; ORAL

	/MEPRIAM/		
/AA/	/LEMMON/	/400MG/	/N16069/001/
	@ LEMMON	400MG	N16069 001

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
METARAMINOL BITARTRATE

/AP/	/FUJISAWA/	/EQ 10MG BASE/ML/	/N80431/001/	> ADD >	AB	ROXANE	EQ 2.5MG BASE	N40054 001
	@ FUJISAWA	EQ 10MG BASE/ML	N80431 001	> ADD >				AUG 01, 1994

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE

AB	MIKART	25MG	N40062 001 JAN 27, 1994
AB		50MG	N40062 002 JAN 27, 1994

METHDILAZINE

/TABLET,/CHEWABLE;/ORAL/
/TACARYL/

/WESTWOOD/SQUIBB/	/3.6MG/	/N11950/009/
@ WESTWOOD SQUIBB	3.6MG	N11950 009

METHDILAZINE HYDROCHLORIDE

/SYRUP;/ORAL/
/TACARYL/

/WESTWOOD/SQUIBB/	/4MG/5ML/	/N11950/007/
@ WESTWOOD SQUIBB	4MG/5ML	N11950 007

/TABLET;/ORAL/
/TACARYL/

/WESTWOOD/SQUIBB/	/8MG/	/N11950/006/
@ WESTWOOD SQUIBB	8MG	N11950 006

METHOTREXATE SODIUM

INJECTABLE; INJECTION
FOLEX PFS

/AP/	/ADRIA/	/EQ 25MG BASE/ML/	/N89180/001/ /JAN/03,/1986/
	@ ADRIA	EQ 25MG BASE/ML	N89180 001 JAN 03, 1986

METHOTREXATE SODIUM

TABLET; ORAL
METHOTREXATE SODIUM

> ADD >	AB	ROXANE	EQ 2.5MG BASE	N40054 001 AUG 01, 1994
> ADD >				

METHSCOPOLAMINE BROMIDE

TABLET; ORAL
PAMINE

AA	BRADLEY	2.5MG	N08848 001
/AA/	/UPJOHN/	/2.5MG/	/N08848/001/

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED

/AP/	/ABBOTT/	/EQ 40MG BASE/VIAL/	/N89573/001/ /FEB/22,/1991/
/AP/		/EQ 125MG BASE/VIAL/	/N89574/001/ /FEB/22,/1991/
/AP/		/EQ 500MG BASE/VIAL/	/N89575/001/ /FEB/22,/1991/
	@ ABBOTT	EQ 40MG BASE/VIAL	N89573 001 FEB 22, 1991
	@	EQ 125MG BASE/VIAL	N89574 001 FEB 22, 1991
	@	EQ 500MG BASE/VIAL	N89575 001 FEB 22, 1991

/METHYLPREDNISOLONE/

/AP/	/ORGANON/	/EQ 500MG BASE/VIAL/	/N87535/001/ /JUN/25,/1982/
/AP/		/EQ 1GM BASE/VIAL/	/N87535/002/ /JUN/25,/1982/
	@ ORGANON	EQ 500MG BASE/VIAL	N87535 001 JUN 25, 1982
	@	EQ 1GM BASE/VIAL	N87535 002 JUN 25, 1982

METHYLTESTOSTERONE

TABLET; BUCCAL/SUBLINGUAL
METHYLTESTOSTERONE

	/PRIVATE/FORM/	/5MG/	/N83836/001/
	@ PRIVATE FORM	5MG	N83836 001
/BP/	/TABLICAPS/	/10MG/	/N85125/001/
	@ TABLICAPS	10MG	N85125 001

METHYLTESTOSTERONE

TABLET; ORAL
METHYLTESTOSTERONE

>_DLT_> /BP/	/DANBURY/PHARMA/	/10MG/	/N80933/001/	
>_DLT_> /BP/		/25MG/	/N80931/001/	
>_ADD_>	@ DANBURY PHARMA	10MG	N80933 001	
>_ADD_>	@	25MG	N80931 001	
/BP/	/PUREPAC/	/10MG/	/N80475/002/	
/BP/		/25MG/	/N80475/003/	
	@ PUREPAC	10MG	N80475 002	
	@	25MG	N80475 003	
/BP/	/TABLICAPS/	/10MG/	/N80313/001/	
/BP/		/25MG/	/N85270/001/	
	@ TABLICAPS	10MG	N80313 001	
	@	25MG	N85270 001	
/BP/	/WEST/WARD/	/10MG/	/N84331/001/	
/BP/		/25MG/	/N84331/002/	
	@ WEST WARD	10MG	N84331 001	
	@	25MG	N84331 002	

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
MAXOLON

AB	KING PHARMS	EQ 10MG BASE	N70106 001 MAR 04, 1986
/AB/	/SMITHKLINE/BEECHAM/	/EQ 10MG BASE/	/N70106/001/ /MAR/04,/1986/

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB	APOTHECON	50MG	N74258 001 JAN 27, 1994
AB		100MG	N74258 002 JAN 27, 1994
AB	COPLEY	50MG	N74333 001 JAN 27, 1994
AB		100MG	N74333 002 JAN 27, 1994
AB	GENEVA PHARMS	50MG	N73288 001 MAR 25, 1994
AB		100MG	N73289 001 MAR 25, 1994
AB	PUREPAC PHARM	50MG	N74380 001 JUL 29, 1994
AB		100MG	N74380 002 JUL 29, 1994

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB	WATSON LABS	50MG	N74217 001 MAY 27, 1994
AB		100MG	N74217 002 MAY 27, 1994

MILRINONE LACTATE

INJECTABLE; INJECTION

>_DLT_>	/MILRINONE/LACTATE/		
>_DLT_>	/+//STERLING/WINTHROP/	/EQ/1MG/BASE/ML/	/N19436/001/ /DEC/31,/1987/
>_DLT_>			
>_ADD_>	PRIMACOR		
>_ADD_>	+ STERLING WINTHROP	EQ 1MG BASE/ML	N19436 001 DEC 31, 1987
>_ADD_>			
>_ADD_>	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER		
>_ADD_>	+ STERLING WINTHROP	EQ 20MG BASE/100ML	N20343 003 AUG 09, 1994
>_ADD_>			
>_ADD_>	@	EQ 10MG BASE/100ML	N20343 001 AUG 09, 1994
>_ADD_>			
>_ADD_>	@	EQ 15MG BASE/100ML	N20343 002 AUG 09, 1994
>_ADD_>			

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL
/MINOCIN/

/@/LEDERLE/	/EQ/50MG/BASE/	/N50451/003/ /AUG/10,/1982/
/@/	/EQ/100MG/BASE/	/N50451/002/ /AUG/10,/1982/
MINOCYCLINE HCL		
LEDERLE	EQ 50MG BASE	N50451 003 AUG 10, 1982
	EQ 100MG BASE	N50451 002 AUG 10, 1982

NADOLOL

TABLET; ORAL
CORGARD

>_ADD_> AB	SQUIBB	120MG		N18063 003
>_ADD_> AB		120MG		N18064 003
>_ADD_> AB	+	160MG		N18063 004
>_ADD_> AB		160MG		N18064 004

NADOLOL

TABLET; ORAL
NADOLOL

>ADD>	AB	COPLEY PHARM	80MG	N74368 001 AUG 31, 1994
>ADD>				
>ADD>	AB		120MG	N74368 002 AUG 31, 1994
>ADD>				
>ADD>	AB		160MG	N74368 003 AUG 31, 1994
>ADD>				

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001
AP		EQ 1GM BASE/VIAL	N61984 002
AP		EQ 2GM BASE/VIAL	N61984 003
AP		EQ 4GM BASE/VIAL	N61984 005
/AP/	/BRISTOL/	/EQ 500MG BASE/VIAL/	/N61984/001/
/AP/		/EQ 1GM BASE/VIAL/	/N61984/002/
/AP/		/EQ 2GM BASE/VIAL/	/N61984/003/
/AP/		/EQ 4GM BASE/VIAL/	/N61984/005/

UNIPEN

AP	WYETH AYERST	EQ 10GM BASE/VIAL	N50320 005
@		EQ 20GM BASE/VIAL	N50320 006

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
/NAFAZAIR/

/AT/	/PHARMAFAIR/	/0.1%/	/N88101/001/ /APR/15,/1983/

NAFAZAIR

AT	BAUSCH AND LOMB	0.1%	N40073 001 MAY 25, 1994
@	PHARMAFAIR	0.1%	N88101 001 APR 15, 1983

NAPROXEN

SUSPENSION; ORAL
NAPROSYN

AB	+ SYNTEX	25MG/ML	N18965 001 MAR 23, 1987

NAPROXEN

AB	ROXANE	25MG/ML	N74190 001 MAR 30, 1994

NAPROXEN

TABLET; ORAL
NAPROSYN

/AB/	/SYNTEX/	/500MG/	/N17581/004/ /APR/15,/1982/
AB	+ SYNTEX	500MG	N17581 004 APR 15, 1982

NAPROXEN

AB	ROXANE	250MG	N74211 001 FEB 28, 1994
AB		375MG	N74211 002 FEB 28, 1994
AB		500MG	N74211 003 FEB 28, 1994

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	COPLEY	EQ 250MG BASE	N74289 001 JAN 27, 1994
AB		EQ 500MG BASE	N74289 002 JAN 27, 1994
>ADD> AB	MYLAN	EQ 250MG BASE	N74367 001 AUG 31, 1994
>ADD>			
>ADD> AB		EQ 500MG BASE	N74367 002 AUG 31, 1994
>ADD>			

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

/AA/	/LANNETT/	/EQ 350MG BASE/	/N60607/001/
@	LANNETT	EQ 350MG BASE	N60607 001

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

	HABITROL			
/BC/	/BASEL/PHARMS/	/7MG/24HR/	/N20076/001/ /NOV/27,/1991/	
BC +	BASEL PHARMS	7MG/24HR	N20076 001 NOV 27, 1991	
/BC/		/14MG/24HR/	/N20076/002/ /NOV/27,/1991/	
BC +		14MG/24HR	N20076 002 NOV 27, 1991	
/BC/		/21MG/24HR/	/N20076/003/ /NOV/27,/1991/	
BC +		21MG/24HR	N20076 003 NOV 27, 1991	

NITROFURANTOIN

TABLET; ORAL

	/FURALAN/		
/AB/	/LANNETT/	/50MG/	/N80017/001/
/AB/		/100MG/	/N80017/002/
	@ LANNETT	50MG	N80017 001
	@	100MG	N80017 002

NITROFURAZONE

OINTMENT; TOPICAL

	NITROFURAZONE		
/AT/	/LANNETT/	/0.2%/	/N84393/001/
	@ LANNETT	0.2%	N84393 001

NITROGLYCERIN

INJECTABLE; INJECTION

	NITROGLYCERIN		
/AP/	/INTL/MEDICATION/	/5MG/ML/	/N70026/001/ /SEP/10,/1985/
	@ INTL MEDICATION	5MG/ML	N70026 001 SEP 10, 1985
	/NITRONAL/		
	/+//BOSKAMP/	/1MG/ML/	/N18672/001/ /AUG/30,/1983/
	@ G POHL BOSKAMP	1MG/ML	N18672 001 AUG 30, 1983

NITROGLYCERIN

INJECTABLE; INJECTION

	NITROSTAT		
/AP/	/PARKE/DAVIS/	/5MG/ML/	/N70863/001/ /JAN/08,/1987/
	@ PARKE DAVIS	5MG/ML	N70863 001 JAN 08, 1987
		/10MG/ML/	/N70871/001/ /JAN/08,/1987/
	@	10MG/ML	N70871 001 JAN 08, 1987
		/10MG/ML/	/N70872/001/ /JAN/08,/1987/
	@	10MG/ML	N70872 001 JAN 08, 1987

NORETHINDRONE

TABLET; ORAL

	/NORLUTIN/		
/+/	/PARKE/DAVIS/	/5MG/	/N10895/002/
	@ PARKE DAVIS	5MG	N10895 002

NYSTATIN

SUSPENSION; ORAL

	NYSTATIN		
AA	BAUSCH AND LOMB	100,000 UNITS/ML	N64042 001 FEB 28, 1994
/AA/	/PHARMAFAIR/	/100,000 UNITS/ML/	/N62541/001/ /JAN/16,/1985/
	@ PHARMAFAIR	100,000 UNITS/ML	N62541 001 JAN 16, 1985

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	MYCOLOG-II		
AT	+ APOTHECON	100,000 UNITS/GM;0.1%	N60576 002 MAY 01, 1985
AT		100,000 UNITS/GM;0.1%	N62606 001 MAY 15, 1985
/AT/	/+//SQUIBB/	/100,000 UNITS/GM;0.1%/	/N60576/002/ /MAY/01,/1985/
/AT/		/100,000 UNITS/GM;0.1%/	/N62606/001/ /MAY/15,/1985/

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

/AT/	/BARRE/	/100,000 UNITS/GM;0.1%/	/N63010/001/ /DEC/20,/1988/
	@ BARRE	100,000 UNITS/GM;0.1%	N63010 001 DEC 20, 1988
/B*/	/CLAY/PARK/	/100,000/UNITS/GM;0.1%/	/N62186/002/ /JUN/06,/1985/
	@ CLAY PARK	100,000 UNITS/GM;0.1%	N62186 002 JUN 06, 1985
/AT/	/PHARMAFAIR/	/100,000 UNITS/GM;0.1%/	/N62657/001/ /JUL/30,/1986/
	@ PHARMAFAIR	100,000 UNITS/GM;0.1%	N62657 001 JUL 30, 1986

OINTMENT; TOPICAL
NYSTATIN-TRIAMCINOLONE ACETONIDE

/AT/	/PHARMADERM/	/100,000 UNITS/GM;0.1%/	/N62603/001/ /OCT/09,/1985/
	@ PHARMADERM	100,000 UNITS/GM;0.1%	N62603 001 OCT 09, 1985

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC

+	ASTRA MERCK	20MG	N19810 001 SEP 14, 1989
/+//MERCK/		/20MG/	/N19810/001/ /SEP/14,/1989/

ORPHENADRINE HYDROCHLORIDE

/TABLET;/ORAL/			
/DISIPAL/			
/3M/		/50MG/	/N10653/001/
@ 3M		50MG	N10653 001

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL

+	SMITHKLINE BEECHAM	EQ 30MG BASE	N20031 003 DEC 29, 1992
		/EQ/30MG/BASE/	/N20031/003/ /DEC/29,/1992/

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM

@ APOTHECON		1,000,000 UNITS/VIAL	N60362 001
@		5,000,000 UNITS/VIAL	N60362 003
@		10,000,000 UNITS/VIAL	N60362 004
@		20,000,000 UNITS/VIAL	N60362 002
/AP/	/SQUIBB/	/1,000,000 UNITS/VIAL/	/N60362/001/
/AP/		/5,000,000 UNITS/VIAL/	/N60362/003/
/AP/		/10,000,000 UNITS/VIAL/	/N60362/004/
/AP/		/20,000,000 UNITS/VIAL/	/N60362/002/

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
/BETAPEN-VK/

>DLT>	/BRISTOL/	/EQ 125MG BASE/5ML/	/N61149/001/
>DLT>/AA/		/EQ 250MG BASE/5ML/	/N61149/002/
>DLT>/AA/			
>ADD>	@ APOTHECON	EQ 125MG BASE/5ML	N61149 001
>ADD>	@	EQ 250MG BASE/5ML	N61149 002

TABLET; ORAL
UTICILLIN VK

>DLT>/AB/	/UPJOHN/	/EQ 500MG BASE/	/N61651/002/
>ADD>	@ UPJOHN	EQ 500MG BASE	N61651 002

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTACARINAT

AP	RHONE POULENC RORER	300MG/VIAL	N73447 001 APR 28, 1994

PENTOBARBITAL SODIUM

CAPSULE; ORAL
/PENTOBARBITAL SODIUM/

/AA/	/LANNETT/	/50MG/	/N85937/001/
/AA/		/100MG/	/N85915/001/
@ LANNETT		50MG	N85937 001
@		100MG	N85915 001

PHENDIMETRAZINE TARTRATE

PILOCARPINE HYDROCHLORIDE

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

/AA/	/ZENITH/	/35MG/		/N85611/001/
	@ ZENITH	35MG		N85611 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

/AA/	/LANNETT/	/30MG/		/N87022/001/ /FEB/03,/1983/
	@ LANNETT	30MG		N87022 001 FEB 03, 1983

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC PLAIN

AA	PENNEX	5MG/5ML;6.25MG/5ML		N88897 001 JAN 04, 1985
/@/		/5MG/5ML;6.25MG/5ML/		/N88897/001/ /JAN/04,/1985/

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
/DIPHENYLAN/SODIUM/

/BX/	/LANNETT/	/100MG/		/N80857/002/
		/30MG/		/N80857/001/
	@ LANNETT	30MG		N80857 001
	@	100MG		N80857 002

PHYTONADIONE

INJECTABLE; INJECTION
PHYTONADIONE

/BP/	/SMITHKLINE/BEECHAM/	/1MG/0.5ML/		/N84060/001/
/BP/		/10MG/ML/		/N84060/002/
	@ SMITHKLINE BEECHAM	1MG/0.5ML		N84060 001
	@	10MG/ML		N84060 002

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL
SALAGEN

	+ MGI	5MG		N20237 001 MAR 22, 1994

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	MUTUAL PHARM	5MG		N74063 001 JAN 27, 1994
AB		10MG		N74063 002 JAN 27, 1994

PIPERAZINE CITRATE

SYRUP; ORAL
/VERMIDOL/

/AA/	/SOLVAY/	/EQ 500MG BASE/5ML/		/N80992/001/
	@ SOLVAY	EQ 500MG BASE/5ML		N80992 001

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	NOVOPHARM	10MG		N73637 001 JAN 28, 1994
AB		20MG		N73638 001 JAN 28, 1994

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

/AP/	/FUJISAWA/	/2MEQ/ML/		/N87885/001/ /FEB/03,/1983/
	@ FUJISAWA	2MEQ/ML		N87885 001 FEB 03, 1983

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

/BX/	/BUNDY/	/5MG/		/N83675/001/
	@ BUNDY	5MG		N83675 001

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

/BX/	/ICN/	/5MG/	/N80236/001/
	@ ICN	5MG	N80236 001
/BX/	/INWOOD/	/5MG/	/N80748/001/
	@ INWOOD	5MG	N80748 001
/BX/	/TABLICAPS/	/5MG/	/N85170/001/
	@ TABLICAPS	5MG	N85170 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

>ADD>		**METIMYD**		
>ADD>	**AT** +	SCHERING	**0.5%;10%**	**N10210 002**
		VASOCIDIN		
>ADD>	**AT**	IOLAB	**0.5%;10%**	**N88791 001**
				OCT 05, 1984
>ADD>				

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

	/PREDAIR FORTE/		
/**AT**/	/PHARMAFAIR/	/**EQ 0.9% PHOSPHATE**/	/N88165/001/
			/MAR/28,/1983/
	@ PHARMAFAIR	EQ 0.9% PHOSPHATE	N88165 001
			MAR 28, 1983

	PREDNISOLONE SODIUM PHOSPHATE		
AT	BAUSCH AND LOMB	**EQ 0.11% PHOSPHATE**	**N40065 001**
			JUL 29, 1994
AT		**EQ 0.9% PHOSPHATE**	**N40070 001**
			JUL 29, 1994

PREDNISONE

TABLET; ORAL
PREDNISONE

/BX/	/BUNDY/	/5MG/	/N83676/001/
	@ BUNDY	5MG	N83676 001
/BX/	/DANBURY/PHARMA/	/50MG/	/N86867/001/
	@ DANBURY PHARMA	50MG	N86867 001
	@ FERRANTE	2.5MG	N80563 001
	@ FERRANTE	5MG	N80563 002
/BX/	/ICN/	/5MG/	/N80237/001/
	@ ICN	5MG	N80237 001
/BX/	/INWOOD/	/1MG/	/N80328/001/
/BX/		/2.5MG/	/N80306/001/
	@ INWOOD	1MG	N80328 001
	@	2.5MG	N80306 001

PREDNISONE

TABLET; ORAL
PREDNISONE

/BX/	/MK/LABS/	/2.5MG/	/N80563/001/
/BX/		/5MG/	/N80563/002/
/BX/	/NYLOS/	/5MG/	/N85115/001/
	@ NYLOS	5MG	N85115 001
/BX/	/REXALL/	/5MG/	/N80232/001/
	@ REXALL	5MG	N80232 001
/BX/	/SPERTI/	/1MG/	/N80359/001/
/BX/		/2.5MG/	/N80359/002/
/BX/		/5MG/	/N80359/003/
	@ SPERTI	1MG	N80359 001
	@	2.5MG	N80359 002
	@	5MG	N80359 003
/BX/	/WHITE/TOWNE/PAULSEN/	/20MG/	/N84913/002/
	@ WHITE TOWNE PAULSEN	20MG	N84913 002
/BX/	/1ST/TX/	/5MG/	/N80371/001/
	@ 1ST TX	5MG	N80371 001

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PROMETHAZINE PLAIN		
AA	PENNEX	**6.25MG/5ML**	**N87953 001**
			NOV 15, 1982
	/@/	/6.25MG/5ML/	/N87953/001/
			/NOV/15,/1982/

TABLET; ORAL
PROMETHAZINE HCL

/BP/	/TABLICAPS/	/12.5MG/	/N84080/001/
/BP/		/25MG/	/N84027/001/
	@ TABLICAPS	12.5MG	N84080 001
	@	25MG	N84027 001
	/REMSED/		
/BP/	/DUPONT/	/25MG/	/N83176/002/
	@ DUPONT	25MG	N83176 002

PROPANTHELINE BROMIDE

TABLET; ORAL

	PRO-BANTHINE		
AA	ROBERTS LABS	**7.5MG**	**N08732 003**
AA		**15MG**	**N08732 002**
/**AA**/	/SCS/	/**7.5MG**/	/N08732/003/
/**AA**/		/**15MG**/	/N08732/002/

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
/KAINAIR/
/AT/ /PHARMAFAIR/ /0.5%/ /N88087/001/
/JUN/07,/1983/
@ PHARMAFAIR 0.5% N88087 001
JUN 07, 1983

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL
>_DLT_> /BD/ /DANBURY/PHARMA/ /50MG/ /N80932/001/
>_ADD_> @ DANBURY PHARMA 50MG N80932 001
/BD/ /LANNETT/ /50MG/ /N80016/001/
@ LANNETT 50MG N80016 001
/BD/ /TABLICAPS/ /50MG/ /N80840/001/
@ TABLICAPS 50MG N80840 001

PROTIRELIN

INJECTABLE; INJECTION
/RELEFACT TRH/
/AP/ /FERRING/LABS/ /0.5MG/ML/ /N18087/001/
THYREL TRH
AP FERRING LABS 0.5MG/ML N18087 001

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
/ALLERFED/
/AA/ /PRIVATE/FORM/ /60MG;2.5MG/ /N88860/001/
/JAN/31,/1985/
@ PRIVATE FORM 60MG;2.5MG N88860 001
JAN 31, 1985

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL
/PYRIDOSTIGMINE/BROMIDE/
/KALI/DUPHAR/ /30MG/ /N89572/001/
/NOV/27,/1990/
@ SOLVAY 30MG N89572 001
NOV 27, 1990

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX
AB + ROBINS AH 300MG N12796 002
QUINIDINE SULFATE
AB COPLEY PHARM 300MG N40045 001
JUN 30, 1994

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
ZANTAC 150
GLAXO EQ 150MG BASE N20095 001
MAR 08, 1994
ZANTAC 300
+ GLAXO EQ 300MG BASE N20095 002
MAR 08, 1994

GRANULE, EFFERVESCENT; ORAL
ZANTAC 150
+ GLAXO EQ 150MG BASE/PACKET N20251 002
MAR 31, 1994

TABLET, EFFERVESCENT; ORAL
ZANTAC 150
+ GLAXO EQ 150MG BASE N20251 001
MAR 31, 1994

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ZEMURON
+ ORGANON 10MG/ML N20214 002
MAR 17, 1994
ZEMURON (P/F)
+ ORGANON 10MG/ML N20214 001
MAR 17, 1994

ROSE BENGAL SODIUM, I-131

INJECTABLE; INJECTION
ROBENGATOPE
>_ADD_> @ BRACCO 0.5mCi/VIAL N16224 001
>_ADD_> @ 1mCi/VIAL N16224 002
>_ADD_> @ 2mCi/VIAL N16224 003

ROSE BENGAL SODIUM, I-131

INJECTABLE; INJECTION
ROBENGATOPE

>DLT>	/@/SQUIBB/	/0.5MCI/VIAL/	/N16224/001/
>DLT>	/@/	/1MCI/VIAL/	/N16224/002/
>DLT>	/@/	/2MCI/VIAL/	/N16224/003/

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION
SEREVENT

+	GLAXO	EQ 0.021MG BASE/INH	N20236 001 FEB 04, 1994

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM

/AA/	/LANNETT/	/**50MG**/	/N85909/001/
/AA/		/**100MG**/	/N85903/001/
	@ LANNETT	50MG	N85909 001
	@	100MG	N85903 001

SECONAL SODIUM

/AA/	/LILLY/	/**50MG**/	/N86101/001/ /OCT/03,/1983/
	LILLY	50MG	N86101 001 OCT 03, 1983

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION
SETHOTOPE

>ADD>	@ BRACCO	85-550uCi/ML	N17047 001
>DLT>	/@/SQUIBB/	/85-550/UCI/ML/	/N17047/001/

SILVER SULFADIAZINE

DRESSING; TOPICAL
SILDIMAC

	/@/BIOPLASTY/	/1%/	/N19608/001/ /NOV/30,/1989/
	@ ENQUAY	1%	N19608 001 NOV 30, 1989

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM

>ADD>	BRACCO	250uCi/VIAL	N13993 001
>ADD>		1mCi/VIAL	N13993 003
>ADD>	@	2mCi/VIAL	N13993 002
>DLT>	/SQUIBB/	/250/UCI/VIAL/	/N13993/001/
>DLT>		/1MCI/VIAL/	/N13993/003/
>DLT>	/@/	/2MCI/VIAL/	/N13993/002/

SODIUM IODIDE, I-131

CAPSULE; ORAL
IODOTOPE

>ADD>	BRACCO	8-100uCi	N10929 001
>ADD>		1-50mCi	N10929 003
>DLT>	/SQUIBB/	/8-100/UCI/	/N10929/001/
>DLT>		/1-50MCI/	/N10929/003/

SOLUTION; ORAL
IODOTOPE

>ADD>	BRACCO	7-106mCi/BOT	N10929 002
>DLT>	/SQUIBB/	/7-106MCI/BOT/	/N10929/002/

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS

/AP/	/ABBOTT/	/**50MG/VIAL**/	/N18450/001/
	@ ABBOTT	50MG/VIAL	N18450 001

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION
PHOSPHOTOPE

>ADD>	@ BRACCO	1-8mCi/VIAL	N10927 001

SOLUTION; INJECTION, ORAL
PHOSPHOTOPE

>DLT>	/@/SQUIBB/	/1-8MCI/VIAL/	/N10927/001/

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE
BERLEX 120MG N19865 005 APR 20, 1994

STAVUDINE

CAPSULE; ORAL
ZERIT
+ BRISTOL MYERS SQUIBB 40MG N20412 005 JUN 24, 1994
@ 5MG N20412 001 JUN 24, 1994
15MG N20412 002 JUN 24, 1994
20MG N20412 003 JUN 24, 1994
30MG N20412 004 JUN 24, 1994

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE
/AP/ /PFIZER/ **/EQ 1GM BASE/2ML/** /N60111/001/
PFIZER EQ 1GM BASE/2.5ML N60111 001

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
/SULFAIR FORTE/
/AT/ /PHARMAFAIR/ **/30%/** /N88385/001/ /OCT/13,/1983/
@ PHARMAFAIR 30% N88385 001 OCT 13, 1983

/SULFAIR-15/
/AT/ /PHARMAFAIR/ **/15%/** /N88186/001/ /MAY/25,/1983/
@ PHARMAFAIR 15% N88186 001 MAY 25, 1983

SULFADIAZINE

TABLET; ORAL
SULFADIAZINE
>DLT>/AB/ /EON/LABS/ **/500MG/** /N40091/001/ /JUL/29,/1994/
>DLT>
>ADD> **AB** + EON LABS **500MG** **N40091 001** JUL 29, 1994
>ADD>
>DLT>/AB//+//LILLY/ **/500MG/** /N04122/002/
>ADD> @ LILLY 500MG N04122 002

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM
/AP/ /FUJISAWA/ **/80MG/ML;16MG/ML/** /N70223/001/ /DEC/29,/1987/
@ FUJISAWA 80MG/ML;16MG/ML N70223 001 DEC 29, 1987

SUSPENSION; ORAL
/BACTRIM/
/AB//+//ROCHE/ **/200MG/5ML;40MG/5ML/** /N17560/001/
@ ROCHE 200MG/5ML;40MG/5ML N17560 001

BACTRIM PEDIATRIC
/AB/ /ROCHE/ **/200MG/5ML;40MG/5ML/** /N17560/002/
AB + ROCHE **200MG/5ML;40MG/5ML** **N17560 002**
TRIMETH/SULFA
/AB/ /BARRE/ **/200MG/5ML;40MG/5ML/** /N72398/001/ /MAY/23,/1988/
@ BARRE 200MG/5ML;40MG/5ML N72398 001 MAY 23, 1988

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM
/AB/ /EON/LABS/ **/400MG;80MG/** /N18598/003/ /MAY/19,/1982/
@ EON LABS 400MG;80MG N18598 003 MAY 19, 1982

/UROPLUS DS/
/AB/ /SHIONOGI/ **/800MG;160MG/** /N71816/001/ /SEP/28,/1987/
@ SHIONOGI 800MG;160MG N71816 001 SEP 28, 1987

/UROPLUS SS/
/AB/ /SHIONOGI/ **/400MG;80MG/** /N71815/001/ /SEP/28,/1987/
@ SHIONOGI 400MG;80MG N71815 001 SEP 28, 1987

SULFASALAZINE

SUSPENSION; ORAL
AZULFIDINE
/+//PHARMACIA/ /250MG/5ML/ /N18605/001/
+ PHARMACIA 250MG/5ML N86983 001
@ 250MG/5ML N18605 001
/250MG/5ML/ /N86983/001/

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE
/**AB**/ /LANNETT/ /**500MG**/ /N80085/001/
@ LANNETT 500MG N80085 001

TACROLIMUS

CAPSULE; ORAL
PROGRAF
+ FUJISAWA EQ 1MG BASE N50708 001
APR 08, 1994
+ EQ 5MG BASE N50708 002
APR 08, 1994

INJECTABLE; INJECTION
PROGRAF
+ FUJISAWA EQ 5MG BASE/ML N50709 001
APR 08, 1994

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
+ ZENECA EQ 20MG BASE N17970 002
MAR 21, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
MACROTEC
>_ADD_> BS BRACCO N/A N17833 001
>_DLT_> /BS/ /SQUIBB/ /N/A/ /N17833/001/

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE; INJECTION
RENOTEC
>_ADD_> @ BRACCO N/A N17045 001
>_DLT_> /@/SQUIBB/ /N/A/ /N17045/001/

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
MDP-SQUIBB
>_ADD_> **AP** BRACCO **N/A** **N18107 001**
>_DLT_>/**AP**/ /SQUIBB/ /**N/A**/ /N18107/001/

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION
/OSTEOSCAN-HDP/
/MALLINCKRODT/ /N/A/ /N18321/001/
TECHNESCAN HDP
MALLINGKRODT N/A N18321 001

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
CARDIOLITE
DUPONT N/A N19785 001
DEC 21, 1990
/DUPONT/MERCK/ /N/A/ /N19785/001/
/DEC/21,/1990/

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
TESULOID
>_ADD_> **AP** BRACCO **N/A** **N16923 001**
>_DLT_>/**AP**/ /SQUIBB/ /**N/A**/ /N16923/001/

TETRACYCLINE

/SYRUP;/ORAL/
/**ACHROMYCIN V**/
/**AB**//+//LEDERLE/ /**EQ 125MG HCL/5ML**/ /N50263/002/
/**SUMYCIN**/
/**AB**/ /SQUIBB/ /**EQ 125MG HCL/5ML**/ /N60400/001/
/**TETRACYCLINE**/
/**AB**/ /BARRE/ /**EQ 125MG HCL/5ML**/ /N60633/001/
/**AB**/ /MK/LABS/ /**EQ 125MG HCL/5ML**/ /N60174/001/

TETRACYCLINE

/SYRUP;/ORAL/
/TETRACYCLINE HCL/
/AB/ /PUREPAC/ /EQ 125MG HCL/5ML/ /N60291/001/
/TETRACYN/
/AB/ /PFIPHARMECS/ /EQ 125MG HCL/5ML/ /N60095/001/
/TETRAMED/
/AB/ /ZENITH/ /EQ 125MG HCL/5ML/ /N61468/001/

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
/AB/ /ICN/ /500MG/ /N60471/002/
@ ICN 500MG N60471 002

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE
+ ON SITE 12.7MG/FIBER N50653 001
MAR 25, 1994

SYRUP; ORAL
ACHROMYCIN V
AB + LEDERLE 125MG/5ML N50263 002
SUMYCIN
AB SQUIBB 125MG/5ML N60400 001
TETRACYCLINE HCL
AB BARRE 125MG/5ML N60633 001
AB MK LABS 125MG/5ML N60174 001
AB PUREPAC 125MG/5ML N60291 001
TETRACYN
AB PFIPHARMECS 125MG/5ML N60095 001
TETRAMED
AB ZENITH 125MG/5ML N61468 001

TABLET; ORAL
/PANMYCIN/
/AB/ /UPJOHN/ /500MG/ /N61705/002/
@ UPJOHN 250MG N61705 001
@ 500MG N61705 002

SUMYCIN
/AB//+//APOTHECON/ /500MG/ /N61147/004/
+ APOTHECON 500MG N61147 004

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
SLO-BID
AB RHONE POULENC RORER 100MG N87892 001
JAN 31, 1985
AB 125MG N89540 001
MAY 10, 1989
AB 200MG N87893 001
JAN 31, 1985
AB + 300MG N87894 001
JAN 31, 1985

THEOPHYLLINE
AB INWOOD LABS 100MG N40052 001
FEB 14, 1994
AB 125MG N40052 002
FEB 14, 1994
AB 200MG N40052 003
FEB 14, 1993
AB 300MG N40052 004
FEB 14, 1994

ELIXIR; ORAL
/LANOPHYLLIN/
/AA/ /LANNETT/ /80MG/15ML/ /N84578/001/
@ LANNETT 80MG/15ML N84578 001

THEOPHYLLINE
/AA/ /BARRE/ /80MG/15ML/ /N89223/001/
/MAY/27,/1988/
@ BARRE 80MG/15ML N89223 001
MAY 27, 1988
@ CENCI 80MG/15ML N87679 001
APR 15, 1982
/AA/ /LIFE/LABS/ /80MG/15ML/ /N87679/001/
/APR/15,/1982/

INJECTABLE; INJECTION
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER
AP BAXTER 4MG/ML N18649 007
JUL 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ABBOTT 4MG/ML N19211 007
DEC 14, 1984
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 4MG/ML N19212 003
NOV 07, 1984

SYRUP; ORAL
>DLT> /ACCURBRON/
>DLT> /MERRELL/DOW/ /150MG/15ML/ /N88746/001/
>DLT> /NOV/22,/1985/

THEOPHYLLINE

SYRUP; ORAL

>_DLT_>	/ACCURBRON/			
>_ADD_>	@ MERRELL DOW	150MG/15ML	N88746 001	
>_ADD_>			NOV 22, 1985	
	/**THEOPHYLLINE**/			
/**AA**/	/BARRE/	/**80MG/15ML**/	/N86001/001/	
	@ BARRE	80MG/15ML	N86001 001	

THYROGLOBULIN

TABLET; ORAL

	PROLOID		
/BP/+//PARKE/DAVIS/		/65MG/	/N02245/002/
		/32MG/	/N02245/005/
	@ PARKE DAVIS	32MG	N02245 005
	@	65MG	N02245 002
		/100MG/	/N02245/008/
	@	100MG	N02245 008
		/130MG/	/N02245/010/
	@	130MG	N02245 010
		/200MG/	/N02245/007/
	@	200MG	N02245 007
	THYROGLOBULIN		
	+ GLOBAL PHARMS	64.8MG	N80151 001
/BP/	/RICHLYN/	/64.8MG/	/N80151/001/

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

	TOBRAMYCIN		
AT	STERIS	**0.3%**	**N63176 001**
			MAY 25, 1994

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

	TOBRAMYCIN SULFATE		
AP	APOTHECON	**EQ 10MG BASE/ML**	**N64021 001**
			MAY 31, 1994
AP		**EQ 40MG BASE/ML**	**N64021 002**
			MAY 31, 1994
AP		**EQ 40MG BASE/ML**	**N64026 001**
			MAY 31, 1994

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	ABBOTT	EQ 1.6MG BASE/ML	N63081 006
			JUN 02, 1993

TOLMETIN SODIUM

TABLET; ORAL

	TOLMETIN SODIUM		
>_ADD_> **AB**	MYLAN	**EQ 600MG BASE**	**N74473 001**
>_ADD_>			AUG 30, 1994

TRIAMCINOLONE

TABLET; ORAL

	TRIAMCINOLONE		
/BP/	/MYLAN/	/2MG/	/N84406/001/
	@ MYLAN	2MG	N84406 001

TRIAMCINOLONE ACETONIDE

AEROSOL; TOPICAL

	KENALOG		
+	APOTHECON	0.147MG/GM	N12104 001
/+//WESTWOOD/SQUIBB/		/0.147MG/GM/	/N12104/001/

CREAM; TOPICAL

	KENALOG		
AT +	APOTHECON	**0.025%**	**N11601 003**
AT +		**0.1%**	**N11601 006**
AT +		**0.5%**	**N83943 001**
/**AT**//+//WESTWOOD/SQUIBB/		/**0.025%**/	/N11601/003/
/**AT**//+/		/**0.1%**/	/N11601/006/
/**AT**//+/		/**0.5%**/	/N83943/001/

OINTMENT; TOPICAL

	KENALOG		
AT +	APOTHECON	**0.025%**	**N11600 003**
AT +		**0.1%**	**N11600 001**
AT +		**0.5%**	**N83944 001**
/**AT**//+//WESTWOOD/SQUIBB/		/**0.025%**/	/N11600/003/
/**AT**//+/		/**0.1%**/	/N11600/001/
/**AT**//+/		/**0.5%**/	/N83944/001/

TRIAZOLAM

TABLET; ORAL

	HALCION		
AB	UPJOHN	**0.125MG**	**N17892 003**
			APR 26, 1985
AB		**0.25MG**	**N17892 001**
			NOV 15, 1982

TRIAZOLAM

TABLET; ORAL
TRIAZOLAM

AB	ALPHAPHARM	**0.125MG**	**N74031 001** MAR 25, 1994
AB		**0.25MG**	**N74031 002** MAR 25, 1994
AB	ROXANE	**0.125MG**	**N74224 001** JUN 01, 1994
AB		**0.25MG**	**N74224 002** JUN 01, 1994

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ARTANE

>DLT>	/+//LEDERLE/	/5MG/	/N06773/010/
>ADD>	+ LEDERLE	5MG	N12947 001
>ADD>	@	5MG	N06773 010
>DLT>		/5MG/	/N12947/001/

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL
/LANTRISUL/

/**AB**/	/LANNETT/	/**500MG/5ML**/	/N80123/002/
	@ LANNETT	167MG/5ML;167MG/5ML; 167MG/5ML	N80123 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
/MYDRIAFAIR/

/**AT**/	/PHARMAFAIR/	/**0.5%**/	/N88274/001/ /SEP/16,/1983/
/**AT**/	/PHARMAFAIR/	/**1%**/	/N88230/001/ /SEP/16,/1983/
	@ PHARMAFAIR	0.5%	N88274 001 SEP 16, 1983
	@	1%	N88230 001 SEP 16, 1983

TROPICAMIDE

AT	BAUSCH AND LOMB	**0.5%**	**N40067 001** JUL 27, 1994
AT		**1%**	**N40064 001** JUL 27, 1994

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ISOPTIN SR

AB	+ KNOLL PHARM	**180MG**	**N19152 002** DEC 15, 1989

VERAPAMIL HCL

AB	BAKER NORTON	**180MG**	**N74330 001** JAN 31, 1994

VINBLASTINE SULFATE

INJECTABLE; INJECTION
VINBLASTINE SULFATE

/**AP**/	/BULL/	/**10MG/VIAL**/	/N89565/001/ /AUG/18,/1987/
AP	FAULDING	**10MG/VIAL**	**N89565 001** AUG 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE

/**AP**/	/FUJISAWA/	/**1MG/ML**/	/N70411/001/ /SEP/10,/1986/
	@ FUJISAWA	1MG/ML	N70411 001 SEP 10, 1986

VINCRISTINE SULFATE PFS

/**AP**/	/BULL/	/**1MG/ML**/	/N71484/001/ /APR/19,/1988/
AP	FAULDING	**1MG/ML**	**N71484 001** APR 19, 1988

ACETAMINOPHEN

SUPPOSITORY; RECTAL
INFANTS' FEVERALL
UPSHER SMITH — 80MG — N18337 004 AUG 26, 1992

TABLET, EXTENDED RELEASE; ORAL
TYLENOL
+ MCNEIL — 650MG — N19872 001 JUN 08, 1994

BACITRACIN

OINTMENT; TOPICAL
BACITRACIN
>_DLT_< /COMBE/ — /500/UNITS/GM/ — /N62799/001/ /MAY/14,/1987/
>_DLT_<
>_ADD_< @ COMBE — 500 UNITS/GM — N62799 001 MAY 14, 1987
>_ADD_<

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MYCELEX-7 COMBINATION PACK
MILES — 1%;100MG — N20389 002 JUN 23, 1994

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHENHYDRAMINE HCL
/BARRE/ — /12.5MG/5ML/ — /N70497/001/ /APR/25,/1989/
@ BARRE — 12.5MG/5ML — N70497 001 APR 25, 1989

IBUPROFEN

TABLET; ORAL
IBUPROFEN
MCNEIL — 200MG — N73019 001 MAR 30, 1994
PRIVATE FORM — 200MG — N73691 001 FEB 25, 1994

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
/HUMULIN/BR/
/+//LILLY/ — /100/UNITS/ML/ — /N19529/001/ /APR/28,/1986/
@ LILLY — 100 UNITS/ML — N19529 001 APR 28, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION
NPH INSULIN
/+//NOVO/NORDISK/ — /40/UNITS/ML/ — /N17929/001/
@ NOVO NORDISK — 40 UNITS/ML — N17929 001

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
NAPHCON-A
+ ALCON — 0.025%;0.3% — N20226 001 JUN 08, 1994

OPCON-A
+ BAUSCH AND LOMB — 0.027%;0.315% — N20065 001 JUN 08, 1994

NAPROXEN SODIUM

TABLET; ORAL
ALEVE
HAMILTON PHARMS — EQ 200MG BASE — N20204 002 JAN 11, 1994

PERMETHRIN

LOTION; TOPICAL
NIX
/+//BURROUGHS/WELLCOME/ — /1%/ — /N19918/001/ /MAY/02,/1990/
+ WARNER WELLCOME — 1% — N19918 001 MAY 02, 1990

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EFIDAC/24
+ CIBA — 240MG — N20021 002 DEC 15, 1992

PSEUDOEPHEDRINE HYDROCHLORIDE

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

/PSEUDOEPHEDRINE/HCL/		
/ALZA/	/240MG/	/N20021/002/
		/DEC/15,/1992/
SUDAFED 12 HOUR		
/+//BURROUGHS/WELLCOME/	/120MG/	/N73585/001/
		/OCT/31,/1991/
+ WARNER WELLCOME	120MG	N73585 001
		OCT 31, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER
BAXTER HLTHCARE
N940404
JUL 28, 1994

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January-August, 1994]

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
8-METHOXSALEN TN= UVADEX	FOR THE PREVENTION OF ACUTE REJECTION OF CARDIAC ALLOGRAFTS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 05/12/94 MA / /
AMINOSALICYLIC ACID TN= PASER GRANULES	TREATMENT OF TUBERCULOSIS INFECTIONS.	JACOBUS PHARMACEUTICAL COMPANY 37 CLEVELAND LANE PRINCETON NJ 08540 DD 02/19/92 MA 06/30/94
AMIODARONE HCL TN= CORDARONE	FOR THE ACUTE TREATMENT AND PROPHYLAXIS OF LIFE-THREATENING VENTRICULAR TACHYCARDIA OR VENTRICULAR FIBRILLATION.	WYETH-AYERST LABORATORIES P.O. BOX 8299 PHILADELPHIA PA 19101-1245 DD 03/16/94 MA / /
AMMONIUM TETRATHIOMOLYBDATE TN=	TREATMENT OF WILSON'S DISEASE.	BREWER, GEORGE J. M.D. UNIVERSITY OF MICHIGAN MEDICAL SCHOOL ANN ARBOR MI 48109-0618 DD 01/31/94 MA / /
ANTIVENIN, POLYVALENT CROTALID (OVINE) FAB TN= CROTAB	TREATMENT OF ENVENOMATIONS INFLICTED BY NORTH AMERICAN CROTALID SNAKES.	THERAPEUTIC ANTIBODIES INC. 1500 21ST AVENUE SOUTH, SUITE 310 NASHVILLE TN 37212 DD 01/12/94 MA / /
ARGININE BUTYRATE TN=	TREATMENT OF SICKLE CELL DISEASE AND BETA THALASSEMIA.	VERTEX PHARMACEUTICALS INC. 40 ALLSTON STREET CAMBRIDGE MA 02139-4211 DD 05/25/94 MA / /
AUTOLYMPHOCYTE THERAPY TN=	TREATMENT OF RENAL CELL CARCINOMA.	CELLCOR INCORPORATED 200 WELLS AVENUE NEWTON MA 02159 DD 07/12/94 MA / /
BETAINE TN=	TREATMENT OF HOMOCYSTINURIA.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 05/16/94 MA / /
BOVINE IMMUNOGLOBULIN CONCENTRATE, CRYPTOSPORIDIUM PARVUM TN= SPORIDIN-G	TREATMENT AND SYMPTOMATIC RELIEF OF CRYPTOSPORIDIUM PARVUM INFECTION OF THE GASTROINTESTINAL TRACT IN IMMUNOCOMPROMISED PATIENTS.	GALAGEN, INCORPORATED 4001 LEXINGTON AVENUE NORTH ARDEN HILLS MN 55126-2998 DD 03/01/94 MA / /
BUPRENORPHINE HYDROCHLORIDE TN=	TREATMENT OF OPIATE ADDICTION IN OPIATE USERS.	RECKITT & COLMAN PHARMACEUTICALS, INC. 1901 HUGUENOT ROAD RICHMOND VA 23235 DD 06/15/94 MA / /
BUSULFAN TN=	FOR USE AS PREPARATIVE THERAPY FOR MALIGNANCIES TREATED WITH BONE MARROW TRANSPLANTATION.	SPARTA PHARMACEUTICALS, INC. P.O. BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 04/21/94 MA / /
BUSULFAN TN=	AS PREPARATIVE THERAPY IN THE TREATMENT OF MALIGNANCIES WITH BONE MARROW TRANSPLANTATION.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 07/28/94 MA / /
CCD 1042 TN=	TREATMENT OF INFANTILE SPASMS.	COCENSYS, INC. 213 TECHNOLOGY DRIVE IRVINE CA 92718 DD 05/25/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
CHIMERIC (MURINE VARIABLE, HUMAN CONSTANT) MAB TO CD20 TN=	TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 06/13/94 MA / /
CHOLINE CHLORIDE TN=	TREATMENT OF CHOLINE DEFICIENCY,SPECIFICALLY THE CHOLINE DEFICIENCY, HEPATIC STEATOSIS, AND CHOLESTASIS, ASSOCIATED WITH LONG-TERM PARENTERAL NUTRITION.	BUCHMAN, ALAN M.D. 6550 FANNIN, SUITE 1122 HOUSTON TX 77030 DD 02/10/94 MA / /
CLADRIBINE TN= LEUSTATIN	TREATMENT OF THE CHRONIC PROGRESSIVE FORM OF MULTIPLE SCLEROSIS.	BEUTLER, ERNEST M.D. 10666 NORTH TORREY PINES ROAD LA JOLLA CA 92037 DD 04/19/94 MA / /
CLONAZEPAM TN= KLONOPIN	TREATMENT OF HYPEREKPLEXIA (STARTLE DISEASE).	HOFFMAN-LA ROCHE, INCORPORATED 340 KINGSLAND STREET NUTLEY NJ 07110-1199 DD 08/04/94 MA / /
CY-1899 TN=	TREATMENT OF CHRONIC ACTIVE HEPATITIS B INFECTION IN HLA-A2 POSITIVE PATIENTS.	CYTEL CORPORATION 3525 JOHN HOPKINS COURT SAN DIEGO CA 92121 DD 03/16/94 MA / /
CYSTEAMINE TN= CYSTAGON	TREATMENT OF NEPHROPATHIC CYSTINOSIS.	MYLAN LABORATORIES, INC 781 CHESTNUT RIDGE ROAD, PO BOX 4310 MORGANTOWN WV 26504-4310 DD 01/25/91 MA 08/15/94
DEHYDROEPIANDROSTERONE TN=	TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND THE REDUCTION IN THE USE OF STERIODS IN STEROID-DEPENDENT SLE PATIENTS.	GENELABS TECHNOLOGIES, INC. 505 PENOBSCOT DRIVE REDWOOD CITY CA 94063 DD 07/13/94 MA / /
DESMOPRESSIN ACETATE TN=	TREATMENT OF MILD HEMOPHILIA A AND VON WILLEBRAND'S DISEASE.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD COLLEGEVILLE PA 19426 DD 01/22/91 MA 03/07/94
ELLIOTT'S B SOLUTION TN=	TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIAS AND ACUTE LYMPHOBLASTIC LYMPHOMAS.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 08/24/94 MA / /
FGN-1 TN=	FOR THE SUPPRESSION AND CONTROL OF COLONIC ADENOMATOUS POLYPS IN THE INHERITED DISEASE ADENOMATOUS POLYPOSIS COLI.	CELL PATHWAYS, INC. 1700 BROADWAY, SUITE 2000 DENVER CO 80290 DD 02/14/94 MA / /
GAMMALINOLENIC ACID TN=	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	ZURIER, ROBERT B. M.D. 55 LAKE AVE. UNIV. OF MASS. MED. CTR. WORCESTER MA 01655 DD 07/27/94 MA / /
HEME ARGINATE TN= NORMOSANG	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	LEIRAS, INCORPORATED 1850 CENTENNIAL PARK DRIVE, SUITE 450 RESTON VA 22091 DD 03/01/94 MA / /
I-131 RADIOLABELED B1 MONOCLONAL ANTIBODY TN=	TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA.	COULTER CORPORATION 11800 S.W. 147 AVENUE, P.O. BOX 169015 MIAMI FL 33116-9015 DD 05/16/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
IMIGLUCERASE TN= CEREZYME	FOR REPLACEMENT THERAPY IN PATIENTS WITH TYPES I, II, AND III GAUCHER'S DISEASE.	GENZYME CORPORATION ONE KENDALL SQUARE CAMBRIDGE MA 02139 DD 11/05/91 MA 05/23/94
ISOBUTYRAMIDE TN=	TREATMENT OF SICKLE CELL DISEASE AND BETA THALASSEMIA.	VERTEX PHARMACEUTICALS INC. 40 ALLSTON STREET CAMBRIDGE MA 02139-4211 DD 05/25/94 MA / /
L-2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID TN= PROCYSTEINE	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	FREE RADICAL SCIENCES, INC. 245 FIRST STREET CAMBRIDGE MA 02142 DD 06/14/94 MA / /
L-CYSTEINE TN=	FOR THE PREVENTION AND LESSENING OF PHOTOSENSITIVITY IN ERYTHROPOIETIC PROTOPORPHYRIA.	TYSON AND ASSOCIATES 12832 SOUTH CHADRON AVENUE HAWTHORNE CA 90250 DD 05/16/94 MA / /
LIPOSOME ENCAPSULATED RECOMBINANT INTERLEUKIN-2 TN=	TREATMENT OF CANCERS OF THE KIDNEY AND RENAL PELVIS.	ONCOTHERAPEUTICS, INC. 1002 EASTPARK BOULEVARD CRANBURY NJ 08512 DD 06/20/94 MA / /
MITOGUAZONE TN=	TREATMENT OF DIFFUSE NON-HODGKIN'S LYMPHOMA, INCLUDING AIDS-RELATED DIFFUSE NON-HODGKIN'S LYMPHOMA.	CTRC RESEARCH FOUNDATION 11812 BECKET STREET POTOMAC MD 20854 DD 03/18/94 MA / /
N-TRIFLUOROACETYLADRIAMYCIN-14-VALERATE TN=	TREATMENT OF CARCINOMA IN SITU OF THE URINARY BLADDER.	ANTHRA PHARMACEUTICALS, INC. 19 CARSON ROAD PRINCETON NJ 08540 DD 05/23/94 MA / /
OXANDROLONE TN= HEPANDRIN	TREATMENT OF MODERATE/SEVERE ACUTE ALCOHOLIC HEPATITIS IN THE PRESENCE OF MODERATE PROTEIN CALORIE MALNUTRITION.	BIO-TECHNOLOGY GENERAL CORP. 70 WOOD AVENUE SOUTH ISELIN NJ 08830 DD 03/18/94 MA / /
PEGASPARGASE TN= ONCASPAR	TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIA (ALL).	ENZON, INC. 40 KINGSBRIDGE ROAD PISCATAWAY NJ 08854-3998 DD 10/20/89 MA 02/01/94
PILOCARPINE TN= SALAGEN	TREATMENT OF XEROSTOMIA INDUCED BY RADIATION THERAPY FOR HEAD AND NECK CANCER.	MGI PHARMA, INC. SUITE 300 E, 9900 BREN ROAD EAST MINNEAPOLIS MN 55343-9667 DD 09/24/90 MA 03/22/94
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF THE RESPIRATORY SYMPTOMS OF CYSTIC FIBROSIS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02124 DD 01/12/94 MA / /
RECOMBINANT VACCINIA (HUMAN PAPILLOMAVIRUS) TN= TA-HPV	TREATMENT OF CERVICAL CANCER.	CANTAB PHARMACEUTICALS RESEARCH, LTD. 184 CAMBRIDGE SCIENCE PARK CAMBRIDGE CB4 4GN UK DD 08/24/94 MA / /
REDUCED L-GLUTATHIONE TN= CACHEXON	TREATMENT OF AIDS-ASSOCIATED CACHEXIA.	TELLURIDE PHARMACEUTICAL CORPORATION 146 FLANDERS DRIVE HILLSBOROUGH NJ 08876-4656 DD 02/14/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD= Date Designated MA= Marketing Approval
RIFAMPIN, ISONIAZID, PYRAZINAMIDE TN= RIFATER	SHORT-COURSE TREATMENT OF TUBERCULOSIS.	MARION MERRELL DOW, INC. P.O. BOX 9627 KANSAS CITY MO 64134-0627 DD 09/12/85 MA 05/31/94
SOMATROPIN TN= NUTROPIN (EXCLUSIVITY NOT APPLICABLE)	FOR USE IN THE LONG-TERM TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE DUE TO A LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION.	GENENTECH, INC. 460 POINT SAN BRUNO BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 03/06/87 MA 03/09/94
SULFADIAZINE TN=	FOR USE IN COMBINATION WITH PYRIMETHAMINE FOR THE TREATMENT OF TOXOPLASMA GONDII ENCEPHALITIS IN PATIENTS WITH AND WITHOUT ACQUIRED IMMUNODEFICIENCY SYNDROME.	EON LABS MANUFACTURING, INC. 227-15 NORTH CONDUIT AVENUE LAURELTON NY 11413 DD 03/14/94 MA 07/29/94
TIZANIDINE HCL TN= ZANAFLEX	TREATMENT OF SPASTICITY ASSOCIATED WITH MULTIPLE SCLEROSIS AND SPINAL CORD INJURY.	ATHENA NEUROSCIENCES, INC. 800F GATEWAY BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 01/31/94 MA / /
TREOSULFAN TN= OVASTAT	TREATMENT OF OVARIAN CANCER.	MEDAC GmbH c/o PRINCETON REG. ASSOC. 65 SOUTH MAIN STREET PENNINGTION NJ 08534 DD 05/16/94 MA / /

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 1994 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ALBUTEROL (METERED DOSE INHALER - *IN VIVO*)	JAN 27, 1994	
FLURBIPROFEN (TABLET)	DEC 24, 1992	FEB 04, 1994
PHENYTOIN (SUSPENSION AND CHEWABLE TABLET)	MAR 04, 1994	
PHENYTOIN SODIUM (CAPSULE, EXTENDED AND PROMPT)	MAR 04, 1994	

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACYCLOVIR TABLET; ORAL	200MG	93 P-0339/ CP1	NOVOPHARM	NEW DOSAGE FORM	APPROVED FEB 08, 1994
ACYCLOVIR SODIUM INJECTABLE; INJECTION	25MG/ML (20ML/VIAL) (40ML/VIAL)	93 P-0469/ CP1	FAULDING	NEW DOSAGE FORM	APPROVED JUN 09, 1994
ESTRADIOL TABLET; ORAL	1.5MG	93 P-0344/ CP1	BRISTOL MYERS SQIBB	NEW STRENGTH	APPROVED JUN 08, 1994
LOPERAMIDE HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	1MG	93 P-0332/ CP1	ELLIS PHARM CONSULTING	NEW DOSAGE FORM	APPROVED FEB 08, 1994
METHYLTESTOSTERONE CAPSULE; ORAL	25MG	93 P-0459/ CP1	ICN	NEW DOSAGE FORM	APPROVED JUN 08, 1994
MORPHINE SULFATE CAPSULE, EXTENDED RELEASE; ORAL	15MG 60MG 100MG	93 P-0446/ CP1	PHARMA CONSULT	NEW DOSAGE FORM	APPROVED JUN 08, 1994
MORPHINE SULFATE CAPSULE, EXTENDED RELEASE; ORAL	90MG	93 P-0446/ CP1	PHARMA CONSULT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUN 08, 1994
PREDNISONE TABLET, CHEWABLE; ORAL	1MG 2.5MG 20MG 50MG	93 P-0333/ CP1	DURA	NEW DOSAGE FORM	APPROVED JUN 08, 1994
PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE CAPSULE, EXTENDED RELEASE; ORAL	120MG 60MG	93 P-0367/ CP1	EURAND AMERICA	NEW DOSAGE FORM	APPROVED FEB 08, 1994

ERRATA

CIMETIDINE TABLET, EFFERVESCENT; ORAL	200MG 300MG 400MG 800MG	93 P-0048/ CP1*	FLEMINGTON PHARM	NEW DOSAGE FORM	APPROVED SEP 18, 1993

*Not previously published

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-21 ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22 REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23 INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24 FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS

REFERENCES
NEW INDICATION

I-99 PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100 TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102 TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103 PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104 TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105 TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106 TREATMENT OF ACROMEGALY
I-107 VAGINAL CANDIDIASIS
I-108 EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109 TYPHOID FEVER

REFERENCES
PATENT USE CODE

U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY
U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94 TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED
U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19872 001	ACETAMINOPHEN; TYLENOL				NDF	JUN 08, 1997
	19806 001	ACRIVASTINE; SEMPREX-D	4650807	MAR 17, 2004	U-93		
			4501893	FEB 26, 2002		NC	MAR 25, 1997
	74346 001	AMINOSALICYLIC ACID; PASER				ODE	JUN 30, 2001
	18700 001	AMRINONE LACTATE; INOCOR	4072746	JUL 31, 1998	U-7	NCE	JUL 31, 1994
	20304 001	APROTININ BOVINE; TRASYLOL				ODE	DEC 29, 2000
	18831 001	ATRACURIUM BESYLATE; TRACRIUM	4179507	DEC 18, 1996		I-108	JUN 06, 1997
	20233 001	BUDESONIDE; RHINOCORT				NCE	FEB 14, 1999
	18731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
	18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
	18343 001	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 002	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 003	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 005	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
	18343 006	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-101	JAN 28, 1997
						I-95	SEP 23, 1996
>ADD>	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
>ADD>						I-109	JUL 21, 1997
>ADD>	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
>ADD>						I-109	JUL 21, 1997
>ADD>	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
>ADD>						I-109	JUL 21, 1997
>ADD>	20392 001	CYSTEAMINE BITARTRATE; CYSTAGON				NCE	AUG 15, 1999
>ADD>						ODE	AUG 15, 2001
>ADD>	20392 002	CYSTEAMINE BITARTRATE; CYSTAGON				NCE	AUG 15, 1999
>ADD>						ODE	AUG 15, 2001
	20355 001	DESMOPRESSIN ACETATE; DESMOPRESSIN ACETATE				NP	MAR 07, 1997
						ODE	MAR 07, 2001
	20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
	20126 001	DOXEPIN HYDROCHLORIDE; ZONALON	4395420	JUL 26, 2000	U-95	NDF	APR 01, 1997
>ADD>	81295 001	ESTRADIOL; ESTRACE				I-76	SEP 08, 1995
	18922 004	ETODOLAC; LODINE	4076831	FEB 28, 1997	U-45	NCE	JAN 31, 1996
	20363 002	FAMCICLOVIR; FAMVIR				NCE	JUN 29, 1999
	20249 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19304 001	FENOFIBRATE; LIPIDIL	4058552	NOV 15, 1994		NCE	DEC 31, 1998
	19949 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19949 002	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19949 003	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19950 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	20322 001	FLUCONAZOLE; DIFLUCAN	4552884	NOV 12, 2002		I-100	DEC 30, 1996
			4302460	NOV 24, 1998		NCE	JAN 29, 1995
						NS	JUN 30, 1997
						I-107	JUN 30, 1997
	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4018895	APR 19, 1994	U-12	I-102	FEB 28, 1997
	18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		I-102	FEB 28, 1997
	20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		I-102	FEB 28, 1997
	20235 001	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20235 002	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20235 003	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20329 001	GLIPIZIDE; GLUCOTROL XL				NDF	APR 26, 1997
	20329 002	GLIPIZIDE; GLUCOTROL XL				NDF	APR 26, 1997
	19778 003	HYDROCHLOROTHIAZIDE; PRINZIDE 10-12.5	4472380	SEP 18, 2001			
			4374829	DEC 30, 2001	U-3	NS	NOV 18, 1996
	19888 001	HYDROCHLOROTHIAZIDE; ZESTORETIC 20-12.5	4472380	SEP 18, 2001			
			4374829	DEC 30, 2001	U-3		
	19888 002	HYDROCHLOROTHIAZIDE; ZESTORETIC 20-25	4374829	DEC 30, 2001	U-3		
	19888 003	HYDROCHLOROTHIAZIDE; ZESTORETIC 10-12.5	4472380	SEP 18, 2001		NS	NOV 18, 1996
			4374829	DEC 30, 2001	U-3		
	20367 001	IMIGLUCERASE; CEREZYME				NCE	MAY 23, 1999
						ODE	MAY 23, 2001
	20314 001	INDIUM IN-111 PENTETREOTIDE KIT; OCTREOSCAN				NCE	JUN 02, 1999
>ADD>	20084 001	IOBENGUANE SULFATE I 131; IOBENGUANE SULFATE I 131	4584187	APR 22, 2003		NCE	MAR 25, 1999
	50705 001	ISONIAZID; RIFATER				ODE	MAY 31, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20336 001	ISRADIPINE; DYNACIRC CR	5030456	JUL 09, 2008			
			4950486	AUG 21, 2007		NDF	JUN 01, 1997
			4946687	AUG 07, 2007		NCE	DEC 20, 1995
			4816263	MAR 28, 2006	U-3		
			4783337	SEP 16, 2003	U-3		
			4466972	AUG 21, 2003	U-3		
	20336 002	ISRADIPINE; DYNACIRC CR	5030456	JUL 09, 2008			
			4950486	AUG 21, 2007		NDF	JUN 01, 1997
			4946687	AUG 07, 2007		NCE	DEC 20, 1995
			4816263	MAR 28, 2006	U-3		
			4783337	SEP 16, 2003	U-3		
			4466972	AUG 21, 2003	U-3		
	20083 001	ITRACONAZOLE; SPORANOX				I-104	MAR 29, 1997
>ADD>	19816 001	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN	4369184	JAN 18, 2000		NCE	NOV 10, 1998
	19558 006	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	20264 001	MEGESTROL ACETATE; MEGACE				NDF	SEP 10, 1997
>ADD>	20343 001	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
>ADD>	20343 002	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
>ADD>	20343 003	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
	20065 001	NAPHAZOLINE HYDROCHLORIDE; OPCON-A				NC	JUN 08, 1997
	20226 001	NAPHAZOLINE HYDROCHLORIDE; NAPHCON-A				NC	JUN 08, 1997
	19667 001	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 002	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 003	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 004	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 005	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	20262 001	PACLITAXEL; TAXOL				I-105	APR 13, 1997
						D-24	JUN 22, 1997
	20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
	20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
	20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
	20184 001	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20184 002	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20184 003	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20237 001	PILOCARPINE HYDROCHLORIDE; SALAGEN				ODE	MAR 22, 2001
					NDF	MAR 22, 1997
20279 001	PREDNICARBATE; DERMATOP				NDF	OCT 29, 1996
19627 001	PROPOFOL; DIPRIVAN				I-99	OCT 26, 1996
20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC/24	4801461	MAY 05, 2004			
		4576604	MAR 18, 2003			
18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4128658	DEC 05, 1995		D-21	FEB 28, 1997
18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4128658	DEC 05, 1995		D-21	FEB 28, 1997
19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4521431	JUN 04, 2002		D-21	FEB 28, 1997
20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	JUL 02, 2008			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	JUL 02, 2008			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20214 001	ROCURONIUM BROMIDE; ZEMURON (P/F)	4894369	JAN 16, 2007		NCE	MAR 17, 1999
20214 002	ROCURONIUM BROMIDE; ZEMURON	4894369	JAN 16, 2007		NCE	MAR 17, 1999
20236 001	SALMETEROL XINAFOATE; SEREVENT	4992474	FEB 12, 2008		NCE	FEB 04, 1999
19766 001	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 004	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19640 001	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				D-23	APR 15, 1997
19640 004	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				D-23	APR 15, 1997
19865 005	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
					ODE	OCT 30, 1999
20412 001	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 002	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 003	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 004	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 005	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	40091 001	SULFADIAZINE; SULFADIAZINE				ODE	JUL 29, 2001
	17376 001	SULFAMETHOXAZOLE; SEPTRA	4209513	JUN 24, 1997		I-103	JAN 07, 1997
	17376 002	SULFAMETHOXAZOLE; SEPTRA DS	4209513	JUN 24, 1997		I-103	JAN 07, 1997
	17377 001	SULFAMETHOXAZOLE; BACTRIM				I-103	JAN 07, 1997
	17377 002	SULFAMETHOXAZOLE; BACTRIM DS				I-103	JAN 07, 1997
	17560 002	SULFAMETHOXAZOLE; BACTRIM PEDIATRIC				I-103	JAN 07, 1997
	17598 001	SULFAMETHOXAZOLE; SEPTRA				I-103	JAN 07, 1997
	17598 002	SULFAMETHOXAZOLE; SEPTRA GRAPE				I-103	JAN 07, 1997
	17970 002	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002			
	19762 001	TESTOSTERONE; TESTODERM	4867982	FEB 16, 2005			
			4725439	FEB 16, 2005			
			4704282	NOV 03, 2004		NDF	OCT 12, 1996
	19762 002	TESTOSTERONE; TESTODERM	4867982	FEB 16, 2005			
			4725439	FEB 16, 2005			
			4704282	NOV 03, 2004		NDF	OCT 12, 1996
	20330 001	TIMOLOL MALEATE; TIMOPTIC-XE	4861760	AUG 29, 2006			
			4195085	MAR 25, 1997		NP	NOV 04, 1996
	20330 002	TIMOLOL MALEATE; TIMOPTIC-XE	4861760	AUG 29, 2006			
			4195085	MAR 25, 1997		NP	NOV 04, 1996
	20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4694007	SEP 15, 2004	U-91	ODE	DEC 17, 2000

New 15th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7542

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $64.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

_____
(Purchase Order No.)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/94)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 512-1800.